

TRAINING UPDATE

Lab Location: SGMC
Department: Core Lab

Date Distributed: 5/26/2021
Due Date: 6/26/2021

DESCRIPTION OF PROCEDURES

Name of procedure:

SOP #	Title
SGMC.C3004	Amylase (AMY-2) by Atellica CH Analyzer
SGMC.C3005	Aspartate Aminotransferase (AST) by Atellica CH Analyzer
SGMC.C3003	Ammonia (Amm) by Atellica CH Analyzer
SGMC.C3002	Alanine Aminotransferase (ALT) by Atellica CH Analyzer
SGMC.C3040	Alkaline Phosphatase (ALP-2c) by Atellica CH Analyzer
SGMC.C3057	Lipase (Lip) by Atellica CH Analyzer
SGMC.C3019	Gamma-Glutamyl Transferase (GGT) by Atellica CH Analyzer

Description of change(s):

These are the new assay SOPs for the Atellica Solution analyzers. Core technical staff must review and be familiar with -

- Specimen requirements
- Reagent, calibrator & QC stability and storage
- Ranges and dilutions

These SOPs were implemented on May 19, 2021

Document your compliance with this training update by taking the quiz in the MTS system.

Technical SOP

Title	Alanine Aminotransferase (ALT) by Atellica CH Analyzer	
Prepared by	Ashkan Chini	Date: 4/25/2021
Owner	Robert SanLuis	Date: 4/25/2021

Laboratory Approval	Local Effective Date:	
Print Name and Title	Signature	Date
<i>Refer to the electronic signature page for approval and approval dates.</i>		

TABLE OF CONTENTS

1.	Test Information.....	2
2.	Analytical Principle	2
3.	Specimen Requirements.....	2
4.	Reagents	3
5.	Calibrators/Standards	4
6.	Quality Control	5
7.	Equipment And Supplies	7
8.	Procedure	7
9.	Calculations.....	8
10.	Reporting Results And Repeat Criteria.....	8
11.	Expected Values.....	9
12.	Clinical Significance.....	10
13.	Procedure Notes	10
14.	Limitations Of Method	10
15.	Safety	11
16.	Related Documents	11
17.	References.....	11
18.	Revision History	11
19.	Addenda	11

1. TEST INFORMATION

Assay	Method/Instrument	Test Code
Alanine Aminotransferase	Atellica CH Analyzer	SGPT

Synonyms/Abbreviations
ALT, SGPT, Included in Batteries/Packages: COMP, LIVP

Department
Chemistry

2. ANALYTICAL PRINCIPLE

The reaction is initiated by the addition of α -Ketoglutarate as a second reagent. The concentration of reduced nicotinamide adenine dinucleotide (NADH) is measured by its absorbance at 340/410 nm and the rate of absorbance decrease is proportional to the alanine aminotransferase (ALT) activity.

3. SPECIMEN REQUIREMENTS

3.1 Patient Preparation

Component	Special Notations
Fasting/Special Diets	N/A
Specimen Collection and/or Timing	Normal procedures for collecting and storing serum and plasma may be used for samples to be analyzed by this method.
Special Collection Procedures	N/A
Other	N/A

3.2 Specimen Type & Handling

Criteria	
Type -Preferred -Other Acceptable	Plasma (Lithium Heparin) Serum
Collection Container	Plasma: Mint green top tube (PST) Serum: Red top tube, Serum separator tube (SST)
Volume - Optimum - Minimum	1.0 mL 0.5 mL

Criteria	
Transport Container and Temperature	Collection container or Plastic vial at room temperature
Stability & Storage Requirements	Room Temperature: To be determined
	Refrigerated: 7 days
	Frozen: 30 days
Timing Considerations	N/A
Unacceptable Specimens & Actions to Take	Specimens that are unlabeled, improperly labeled, or those that do not meet the stated criteria are unacceptable. Request a recollection and credit the test with the appropriate LIS English text code for “test not performed” message. Examples: Quantity not sufficient-QNS; Wrong collection-UNAC. Document the request for recollection in the LIS.
Compromising Physical Characteristics	Gross hemolysis. Reject sample and request a recollection. Credit the test with the appropriate LIS English text code explanation of HMT (Specimen markedly hemolyzed)
Other Considerations	Allow Red Top or SST to clot completely prior to centrifugation. Before placing on system, ensure samples are free of: <ul style="list-style-type: none"> • Bubbles or foam • Fibrin or other particulate matter

NOTE: Labeling requirements for all reagents, calibrators and controls include: (1) Open date, (2) Substance name, (3) Lot number, (4) Date of preparation, (5) Expiration date, (6) Initials of tech, and (7) Any special storage instructions. Check all for visible signs of degradation. When placed onboard the analyzer, the instrument captures the date / time loaded and calculates and tracks the opened expiration.

4. REAGENTS

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

4.1 Reagent Summary

Reagents	Supplier & Catalog Number
Alanine Aminotransferase (ALT)	Siemens, Atellica CH, Cat. No. 11097605

4.2 Reagent Preparation and Storage

Reagent	Alanine Aminotransferase (ALT)
Storage	Store at 2-8°C
Stability	Reagents are stable onboard the system for 90 days
Preparation	Reagent is liquid and ready to use.

5. CALIBRATORS/STANDARDS

5.1 Calibrators/Standards Used

Calibrator	Supplier and Catalog Number
ENZ 2 Calibrator (ENZ 2 CAL)	Siemens Atellica CH, Cat. No. 11099318

5.2 Calibrator Preparation and Storage

Calibrator	ENZ 2 Calibrator (ENZ 2 CAL)
Preparation	Calibrators are liquid and ready to use.
Storage/Stability	<ul style="list-style-type: none"> • Store at 2-8°C • Protect from heat and light sources • Unopened: stable until expiration date stamped on the box. • Opened: remains stable for 30 days when recapped immediately after use.

5.3 Calibration Parameter

Criteria	Special Notations
Reference Material	ENZ 2 Calibrator (ENZ 2 CAL)
Assay Range	See Package Insert for specific assay ranges.
Suggested Calibration Level	See Reagent Package Insert for lot specific assigned values in U/L
Frequency	<ul style="list-style-type: none"> • When changing lot numbers of primary reagent packs. • At the end of the lot calibration interval (131 days), for a specified lot of calibrated reagent on the system. • At the end of pack calibration interval (30 days), for calibrated reagent packs on the system. • When indicated by quality control results. • After major maintenance or service. <p>At the end of the onboard stability interval, replace the reagent pack on the system with a new reagent pack. Recalibration is not required, unless the lot calibration interval is exceeded.</p>
Calibration Scheme	See Package Insert for specific calibration scheme.
Procedure	Refer to the Atellica Solution Operating, QC, Calibration and Maintenance procedure for specific instructions.

5.4 Tolerance Limits

IF.....	THEN.....
If result fall within assay-specific specification, and QC values are within acceptable limits,	proceed with analysis
If result falls outside assay-specific specification, or QC values are out of Acceptable limits,	troubleshoot the assay and/or instrument and repeat calibration

6. QUALITY CONTROL

6.1 Controls Used

Controls	Supplier and Catalog Number
InteliQ Assayed Multiquel Control Levels 1 & 3	Bio-Rad Laboratories Cat. No. 12008256, 12008258

6.2 Control Preparation and Storage

Control	InteliQ Assayed Multiquel Control Levels 1 & 3
Preparation	Allow to stand at room temperature (18-25C) until completely thawed but not more than one (1) hour. Once thawed, gently invert several times to ensure homogeneity.
Storage/Stability	Frozen: until the expiration date if unopened at -20 to -70C Thawed and Unopened: 30 days at 2-8C for ALT Thawed and Opened: 14 days at 2-8C for ALT Note: stability varies by assay

6.3 Frequency

Analyze all levels of QC material after every calibration and each day of testing (notated on the QC frequency sheets posted on the instruments).

Refer to the Siemens Atellica QC Schedule and the Siemens Atellica Quick Reference Guide.

6.4 Tolerance Limits and Criteria for Acceptable QC

Step	Action
1	Acceptable ranges for QC are programmed into the instrument's Quality Control software system and Unity Real Time, and may be posted near the instrument for use during computer downtime.

Step	Action
2	<p>Run Rejection Criteria</p> <ul style="list-style-type: none"> Anytime the established parameters are exceeded (if one QC result exceeds 2 SD), the run is considered out of control (failed) and patient results must not be reported. The technologist must follow the procedure in the Laboratory QC Program to resolve the problem.
3	<p>Corrective Action:</p> <ul style="list-style-type: none"> All rejected runs must be effectively addressed through corrective action. Steps taken in response to QC failures must be documented. Patient samples in failed analytical runs must be <u>reanalyzed according to the Laboratory QC Program</u>. Supervisors may override rejection of partial or complete runs only with detailed documentation and criteria for overrides that are approved by the Medical Director. Consult corrective action guidelines in Laboratory QC Program. Follow corrective action guidelines in the Laboratory QC Program. Corrective action documentation must follow the Laboratory Quality Control Program.
4	<p>Review of QC</p> <ul style="list-style-type: none"> QC must be reviewed weekly by the Group Lead or designee and monthly by the Supervisor/Manager or designee. If the SD and/or CV are greater than established ranges, investigate the cause for the imprecision and document implementation of corrective actions.

6.5 Documentation

- QC tolerance limits are programmed into the instrument and Unity Real Time; it calculates cumulative mean, SD and CV and stores all information for easy retrieval.
- Quality control records are reviewed daily at the bench, weekly by the Group Lead or designee, and monthly by the Supervisor/Manager or designee.
- Refer to complete policies and procedures for QC documentation and for record retention requirements in the Laboratory QC Program.

6.6 Quality Assurance Program

- Each new lot number of reagent or new shipment of the same lot of reagent must be tested with external control materials and previously analyzed samples. Performance of the new lot must be equivalent to the previous lot; utilize published TEA for acceptability criteria.
- Training must be successfully completed and documented prior to performing this test. This procedure must be incorporated into the departmental competency assessment program.

- The laboratory participates in CAP proficiency testing. All proficiency testing materials must be treated in the same manner as patient samples.
- Monthly QC must be presented to the Medical Director or designee for review and signature.
- Monthly QC mean and SD are sent to Bio-Rad Laboratories for peer group comparison.
- Consult the Laboratory QC Program for complete details.

7. EQUIPMENT and SUPPLIES

7.1 Assay Platform

Siemens Atellica CH Analyzer

7.2 Equipment

- Refrigerator capable of sustaining 2–8°C.
- Freezer capable of sustaining range not to exceed -20 to -70°C.
- Centrifuge

7.3 Supplies

- System Fluids
- Assorted calibrated pipettes (MLA or equivalent) and disposable tips

8. PROCEDURE

Atellica CH Alanine Aminotransferase (ALT) is required to perform this test.

Alanine Aminotransferase is performed on the Atellica CH Analyzer after the method is calibrated and Quality Controls are acceptable.

NOTE: For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

8.1	Instrument Set-up Protocol
1.	Perform any required instrument maintenance.
2.	Ensure that the instrument has sufficient primary and ancillary reagents.
3.	Check status of cuvettes and tips. Check waste levels. Fill or empty as appropriate.
4.	Check calibration status and re-calibrate as needed.

8.2	Specimen Testing
1.	Centrifuge the specimens.

8.2	Specimen Testing
2.	Load the sample in the Atellica rack and place the rack into the Sample Handler to initiate testing. **NOTE: If not equipped with an in-line decapper unit, samples must be de-capped prior to loading on the Atellica system
3.	Refer to the general operating procedure for detailed steps.
4.	Follow protocol in section 10.6 “Repeat Criteria and Resulting” for samples with results above the analytical measurement range (AMR). Investigate any flagged results and repeat as necessary.
5.	Append the appropriate English text code qualifier messages to any samples requiring a comment regarding sample quality and/or any other pertinent factors.

NOTE: In the event that the test system becomes inoperable, notify supervision or designee for further direction. Patient specimens must be stored in a manner that maintains the integrity of the specimen.

9. CALCULATIONS

The instrument automatically calculates the concentration of Alanine Aminotransferase in U/L.

10. REPORTING RESULTS AND REPEAT CRITERIA

10.1 Interpretation of Data

None required

10.2 Rounding

No rounding is necessary. Instrument reports results as a whole number.

10.3 Units of Measure

U/L

10.4 Clinically Reportable Range (CRR)

7 – 3300 U/L

10.5 Review Patient Data

Each result is reviewed for error messages. Resolve any problems noted before issuing patient reports.

10.6 Repeat Criteria and Resulting

All repeats must replicate the original result within the total allowable error (TEa) of the assay. Refer to TEa listing for specific information.

Values that fall below or within the AMR or CRR may be reported without repeat.
 Values that exceed the upper ranges must be repeated.

IF the result is ...	THEN...
< 7 U/L	Assure there is sufficient sample devoid of bubbles, cellular debris, and/or fibrin clots. Report as: < 7 U/L
≥ 1100 U/L	On Board Automated Dilution: Results ≥ 1100 U/L will automatically have repeat testing performed into the instrument using dilution factor of 3. No multiplication is necessary.
> 3300 U/L	If the recommended dilution does not give results within the clinically reportable range, report as: "> 3300 U/L -REP" Bring to the attention of Tech in Charge (TIC) or Group Lead to check for integrity issues prior to release of results.

Message	Code
Verified by repeat analysis	Append -REP to the result.

11. EXPECTED VALUES

11.1 Reference Ranges

Age	Female	Male
Adult (>19 years):	11 - 66 U/L	11 - 66 U/L
Pediatric:		
16 – 19 years	19 - 49	24 - 54
14 – 15 years	19 - 44	24 - 59
12 – 13 years	24 - 44	24 - 68
10 – 11 years	24 - 44	24 - 49
4 – 9 years	24 - 49	24 - 49
1 – 3 years	24 - 59	19 - 59
7 – 11 months	26 - 55	26 - 59
4 – 6 months	26 - 51	26 - 55
1 – 3 months	26 - 61	27 - 54
8 days – 30 days	22 - 46	24 - 54
0 – 7 days	21 - 54	20 - 54

11.2 Critical Values

None established

11.3 Standard Required Messages

None established

12. CLINICAL SIGNIFICANCE

Measurements of alanine aminotransferase are used in the diagnosis and treatment of certain liver diseases and heart diseases. Significant elevations of alanine aminotransferase are found in diseases of the liver, such as hepatitis, necrosis, jaundice and cirrhosis. Alanine aminotransferase levels can be elevated even before clinical jaundice appears.

13. PROCEDURE NOTES

- **FDA Status:** FDA Approved/cleared
- **Validated Test Modifications:** None

The instrument reporting system contains error messages to warn the operator of specific malfunctions. Any report slip containing such error messages should be held for follow-up.

14. LIMITATIONS OF METHOD

14.1 Analytical Measurement Range (AMR)

7 – 1100 U/L

14.2 Precision

Material	Mean U/L	Standard Deviation (%CV)	
		Repeatability	Within-Lab
Control 1	27	0.34	2.8
Plasma Pool	79	1.34	2.2
Serum Pool	843	2.20	1.0

14.3 Interfering Substances

HIL Interference:

Interfering substances at the levels indicated in the table below were tested in accordance with CLSI Document EP07-A2.

Substance tested	Substance Concentration	U/L	Bias %
Hemoglobin	450 mg/dL	48	5
Bilirubin (unconjugated)	30 mg/dL	41	-4
Bilirubin (conjugated)	30 mg/dL	44	0
Lipemia Intralipid®	450 mg/dL	44	2

14.4 Clinical Sensitivity/Specificity/Predictive Values

Detection Capability

The assay is designed to have a limit of blank (LoB) < limit of detection (LoD) and $LoD \leq 7$ U/L. The LoD corresponds to the lowest concentration of alanine aminotransferase that can be detected with a probability of 95%. The LoD for the

Atellica CH ALT assay is 2 U/L, and was determined using 120 determinations, with 60 blank and 60 low level replicates, and a LoB of 1 U/L.

15. SAFETY

Refer to your local and corporate safety manuals and Safety Data Sheet (SDS) for detailed information on safety practices and procedures and a complete description of hazards.

16. RELATED DOCUMENTS

1. Atellica Solution Operating, QC, Calibration and Maintenance procedure
2. Laboratory Quality Control Program
3. QC Schedule for Siemens Atellica Solution
4. Laboratory Safety Manual
5. Safety Data Sheets (SDS)
6. Atellica Solution Limits Chart
7. Quest Diagnostics Records Management Procedure
8. Atellica Solution System Error Messages Chart
9. Centrifuge Use, Maintenance and Function Checks (Lab policy)
10. Specimen Acceptability Requirements (Lab policy)
11. Repeat Testing Requirement (Lab policy)
12. Current Allowable Total Error Specifications at http://questnet1.qdx.com/Business_Groups/Medical/qc/docs/qc_bpt_tea.xls
13. Current package insert of Alanine Aminotransferase Reagent

17. REFERENCES

1. Ghoshal, Amit K. and Soldin, Steven J., Evaluation of the Dade Behring Dimension[®] RxL: Integrated chemistry system-pediatric reference ranges. Clinica Chimica Acta 2003; 331:144
2. Package Insert, Alanine Aminotransferase Reagent, Siemens Healthcare Diagnostics Inc., 08/2020.
3. Package Insert, ENZ 2 Calibrator (ENZ 2 CAL), Siemens Healthcare Diagnostics Inc., 07/2019.
4. Package Insert, IntelliQ Assayed Multiquel Controls, Bio-Rad Laboratories, 07/2020

18. REVISION HISTORY

Version	Date	Section	Reason	Reviser	Approval

19. ADDENDA

None

Technical SOP

Title	Aspartate Aminotransferase (AST) by Atellica CH Analyzer	
Prepared by	Ashkan Chini	Date: 4/25/2021
Owner	Robert SanLuis	Date: 4/25/2021

Laboratory Approval	Local Effective Date:	
Print Name and Title	Signature	Date
<i>Refer to the electronic signature page for approval and approval dates.</i>		

TABLE OF CONTENTS

1.	Test Information.....	2
2.	Analytical Principle	2
3.	Specimen Requirements.....	2
4.	Reagents	3
5.	Calibrators/Standards	4
6.	Quality Control	5
7.	Equipment And Supplies	7
8.	Procedure	7
9.	Calculations.....	8
10.	Reporting Results And Repeat Criteria.....	8
11.	Expected Values.....	9
12.	Clinical Significance.....	10
13.	Procedure Notes	10
14.	Limitations Of Method	10
15.	Safety	11
16.	Related Documents	11
17.	References.....	11
18.	Revision History	11
19.	Addenda	11

1. TEST INFORMATION

Assay	Method/Instrument	Test Code
Aspartate Aminotransferase	AtellicaCH Analyzer	SGOT

Synonyms/Abbreviations
AST, SGOT, Included in Batteries/Packages: COMP, LIVP

Department
Chemistry

2. ANALYTICAL PRINCIPLE

The concentration of reduced nicotinamide adenine dinucleotide (NADH) is measured by its absorbance at 340/410 nm, and the rate of absorbance decrease is proportional to the AST activity. The reaction is initiated by the addition of α -Ketoglutarate as a second reagent.

3. SPECIMEN REQUIREMENTS

3.1 Patient Preparation

Component	Special Notations
Fasting/Special Diets	N/A
Specimen Collection and/or Timing	Normal procedures for collecting and storing serum and plasma may be used for samples to be analyzed by this method.
Special Collection Procedures	N/A
Other	N/A

3.2 Specimen Type & Handling

Criteria	
Type -Preferred -Other Acceptable	Plasma (Lithium Heparin) Serum
Collection Container	Plasma: Mint green top tube (PST) Serum: Red top tube, Serum separator tube (SST)
Volume - Optimum - Minimum	1.0 mL 0.5 mL
Transport Container and Temperature	Collection container or Plastic vial at room temperature

Criteria	
Stability & Storage Requirements	Room Temperature: 3 days
	Refrigerated: 7 days
	Frozen: 30 days
Timing Considerations	N/A
Unacceptable Specimens & Actions to Take	Specimens that are unlabeled, improperly labeled, or those that do not meet the stated criteria are unacceptable. Request a recollection and credit the test with the appropriate LIS English text code for “test not performed” message. Examples: Quantity not sufficient-QNS; Wrong collection-UNAC. Document the request for recollection in the LIS.
Compromising Physical Characteristics	Gross hemolysis. Reject sample and request a recollection. Credit the test with the appropriate LIS English text code explanation of HMT (Specimen markedly hemolyzed)
Other Considerations	Allow Red Top or SST to clot completely prior to centrifugation. Before placing on system, ensure samples are free of: <ul style="list-style-type: none"> • Bubbles or foam • Fibrin or other particulate matter

NOTE: Labeling requirements for all reagents, calibrators and controls include: (1) Open date, (2) Substance name, (3) Lot number, (4) Date of preparation, (5) Expiration date, (6) Initials of tech, and (7) Any special storage instructions. Check all for visible signs of degradation. When placed onboard the analyzer, the instrument captures the date / time loaded and calculates and tracks the opened expiration.

4. REAGENTS

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

4.1 Reagent Summary

Reagents	Supplier & Catalog Number
Aspartate Aminotransferase (AST)	Siemens, Atellica CH, Cat. No. 11097607

4.2 Reagent Preparation and Storage

Reagent	Aspartate Aminotransferase (AST)
Storage	Store at 2-8°C
Stability	Reagents are stable onboard the system for 90 days
Preparation	Reagent is liquid and ready to use.

5. CALIBRATORS/STANDARDS

5.1 Calibrators/Standards Used

Calibrator	Supplier and Catalog Number
ENZ 2 Calibrator (ENZ 2 CAL)	Siemens Atellica CH, Cat. No. 11099318

5.2 Calibrator Preparation and Storage

Calibrator	ENZ 2 Calibrator (ENZ 2 CAL)
Preparation	Calibrators are liquid and ready to use.
Storage/Stability	<ul style="list-style-type: none"> • Store at 2-8°C • Protect from heat and light sources • Unopened: stable until expiration date stamped on the box. • Opened: remains stable for 30 days when recapped immediately after use.

5.3 Calibration Parameter

Criteria	Special Notations
Reference Material	ENZ 2 Calibrator (ENZ 2 CAL)
Assay Range	See Package Insert for specific assay ranges.
Suggested Calibration Level	See Reagent Package Insert for lot specific assigned values in U/L
Frequency	<ul style="list-style-type: none"> • When changing lot numbers of primary reagent packs. • At the end of the lot calibration interval (131 days), for a specified lot of calibrated reagent on the system. • At the end of pack calibration interval (30 days), for calibrated reagent packs on the system. • When indicated by quality control results. • After major maintenance or service. <p>At the end of the onboard stability interval, replace the reagent pack on the system with a new reagent pack. Recalibration is not required, unless the lot calibration interval is exceeded.</p>
Calibration Scheme	See Package Insert for specific calibration scheme.
Procedure	Refer to the Atellica Solution Operating, QC, Calibration and Maintenance procedure for specific instructions.

5.5 Tolerance Limits

IF.....	THEN.....
If result fall within assay-specific specification, and QC values are within acceptable limits,	proceed with analysis
If result falls outside assay-specific specification, or QC values are out of Acceptable limits,	troubleshoot the assay and/or instrument and repeat calibration

6. QUALITY CONTROL

6.1 Controls Used

Controls	Supplier and Catalog Number
InteliQ Assayed Multiquel Control Levels 1 & 3	Bio-Rad Laboratories Cat. No. 12008256, 12008258

6.2 Control Preparation and Storage

Control	InteliQ Assayed Multiquel Control Levels 1 & 3
Preparation	Allow to stand at room temperature (18-25C) until completely thawed but not more than one (1) hour. Once thawed, gently invert several times to ensure homogeneity.
Storage/Stability	Frozen: until the expiration date if unopened at -20 to -70C Thawed and Unopened: 30 days at 2-8C for AST Thawed and Opened: 9 days at 2-8C for AST Note: stability varies by assay

6.3 Frequency

Analyze all levels of QC material after every calibration and each day of testing (notated on the QC frequency sheets posted on the instruments).

Refer to the Siemens Atellica QC Schedule and the Siemens Atellica Quick Reference Guide.

6.4 Tolerance Limits and Criteria for Acceptable QC

Step	Action
1	Acceptable ranges for QC are programmed into the instrument's Quality Control software system and Unity Real Time, and may be posted near the instrument for use during computer downtime.

Step	Action
2	<p>Run Rejection Criteria</p> <ul style="list-style-type: none"> Anytime the established parameters are exceeded (if one QC result exceeds 2 SD), the run is considered out of control (failed) and patient results must not be reported. The technologist must follow the procedure in the Laboratory QC Program to resolve the problem.
3	<p>Corrective Action:</p> <ul style="list-style-type: none"> All rejected runs must be effectively addressed through corrective action. Steps taken in response to QC failures must be documented. Patient samples in failed analytical runs must be <u>reanalyzed according to the Laboratory QC Program</u>. Supervisors may override rejection of partial or complete runs only with detailed documentation and criteria for overrides that are approved by the Medical Director. Consult corrective action guidelines in Laboratory QC Program. Follow corrective action guidelines in the Laboratory QC Program. Corrective action documentation must follow the Laboratory Quality Control Program.
4	<p>Review of QC</p> <ul style="list-style-type: none"> QC must be reviewed weekly by the Group Lead or designee and monthly by the Supervisor/Manager or designee. If the SD and/or CV are greater than established ranges, investigate the cause for the imprecision and document implementation of corrective actions.

6.5 Documentation

- QC tolerance limits are programmed into the instrument and Unity Real Time; it calculates cumulative mean, SD and CV and stores all information for easy retrieval.
- Quality control records are reviewed daily at the bench, weekly by the Group Lead or designee, and monthly by the Supervisor/Manager or designee.
- Refer to complete policies and procedures for QC documentation and for record retention requirements in the Laboratory QC Program.

6.6 Quality Assurance Program

- Each new lot number of reagent or new shipment of the same lot of reagent must be tested with external control materials and previously analyzed samples. Performance of the new lot must be equivalent to the previous lot; utilize published TEA for acceptability criteria.
- Training must be successfully completed and documented prior to performing this test. This procedure must be incorporated into the departmental competency assessment program.

- The laboratory participates in CAP proficiency testing. All proficiency testing materials must be treated in the same manner as patient samples.
- Monthly QC must be presented to the Medical Director or designee for review and signature.
- Monthly QC mean and SD are sent to Bio-Rad Laboratories for peer group comparison.
- Consult the Laboratory QC Program for complete details.

7. EQUIPMENT and SUPPLIES

7.1 Assay Platform

Siemens Atellica CH Analyzer

7.2 Equipment

- Refrigerator capable of sustaining 2–8°C.
- Freezer capable of sustaining range not to exceed -20 to -70°C.
- Centrifuge

7.3 Supplies

- System Fluids
- Assorted calibrated pipettes (MLA or equivalent) and disposable tips

8. PROCEDURE

Atellica CH Aspartate Aminotransferase (AST) is required to perform this test.

Aspartate Aminotransferase is performed on the Atellica CH Analyzer after the method is calibrated and Quality Controls are acceptable.

NOTE: For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

8.1	Instrument Set-up Protocol
1.	Perform any required instrument maintenance.
2.	Ensure that the instrument has sufficient primary and ancillary reagents.
3.	Check status of cuvettes and tips. Check waste levels. Fill or empty as appropriate.
4.	Check calibration status and re-calibrate as needed.

8.2	Specimen Testing
1.	Centrifuge the specimens.

8.2	Specimen Testing
2.	Load the sample in the Atellica rack and place the rack into the Sample Handler to initiate testing. **NOTE: If not equipped with an in-line decapper unit, samples must be de-capped prior to loading on the Atellica system
3.	Refer to the general operating procedure for detailed steps.
4.	Follow protocol in section 10.6 “Repeat Criteria and Resulting” for samples with results above the analytical measurement range (AMR). Investigate any flagged results and repeat as necessary.
5.	Append the appropriate English text code qualifier messages to any samples requiring a comment regarding sample quality and/or any other pertinent factors.

NOTE: In the event that the test system becomes inoperable, notify supervision or designee for further direction. Patient specimens must be stored in a manner that maintains the integrity of the specimen.

9. CALCULATIONS

The instrument automatically calculates the concentration of Aspartate Aminotransferase in U/L.

10. REPORTING RESULTS AND REPEAT CRITERIA

10.1 Interpretation of Data

None required

10.2 Rounding

No rounding is necessary. Instrument reports results as a whole number.

10.3 Units of Measure

U/L

10.4 Clinically Reportable Range (CRR)

8 – 6000 U/L

10.5 Review Patient Data

Each result is reviewed for error messages. Resolve any problems noted before issuing patient reports.

10.6 Repeat Criteria and Resulting

All repeats must replicate the original result within the total allowable error (TEa) of the assay. Refer to TEa listing for specific information.

Values that fall below or within the AMR or CRR may be reported without repeat.
 Values that exceed the upper ranges must be repeated.

IF the result is ...	THEN...
< 8 U/L	Assure there is sufficient sample devoid of bubbles, cellular debris, and/or fibrin clots. Report as: < 8 U/L
≥ 1000 U/L	On Board Automated Dilution: Results ≥ 1000 U/L will automatically have repeat testing performed into the instrument using dilution factor of 6. No multiplication is necessary.
> 6000 U/L	If the recommended dilution does not give results within the clinically reportable range, report as: "> 6000 U/L -REP" Bring to the attention of Tech in Charge (TIC) or Group Lead to check for integrity issues prior to release of results.

Message	Code
Verified by repeat analysis	Append –REP to the result.

11. EXPECTED VALUES

11.1 Reference Ranges

Age	Female	Male
Adult (>19 years):	15 - 37 U/L	15 - 37 U/L
Pediatric:		
16 – 19 years	0 - 26	10 - 41
12 – 15 years	5 - 26	10 - 36
7 – 11 years	5 - 36	10 - 36
5 – 6 years	10 - 47	10 - 47
1 – 4 years	16 - 57	16 - 57
7 – 11 months	16 - 60	16 - 52
4 – 6 months	16 - 60	16 - 62
1 – 3 months	16 - 61	16 - 60
8 – 30 days	20 - 69	16 - 67
0–7 days	20 - 93	26 - 98

11.2 Critical Values

None established

11.3 Standard Required Messages

None established

12. CLINICAL SIGNIFICANCE

The aspartate aminotransferase method is an adaptation of the methodology recommended by the International Federation of Clinical Chemistry (IFCC). The method uses the coenzyme pyridoxal-5-phosphate (P5P) to activate the apoenzyme and lactic acid dehydrogenase (LDH) to eliminate pyruvate interference. Significant elevations of AST are found in diseases of the liver such as hepatitis, necrosis, jaundice, and cirrhosis. AST levels can be elevated even before clinical jaundice appears.

13. PROCEDURE NOTES

- **FDA Status:** FDA Approved/cleared
- **Validated Test Modifications:** None

The instrument reporting system contains error messages to warn the operator of specific malfunctions. Any report slip containing such error messages should be held for follow-up.

14. LIMITATIONS OF METHOD

14.1 Analytical Measurement Range (AMR)

8 – 1000 U/L

14.2 Precision

Material	Mean U/L	Standard Deviation (%CV)	
		Repeatability	Within-Lab
Plasma Pool	30	0.88	3.4
Control 1	116	1.45	1.7
Serum Pool	861	3.81	0.9

14.3 Interfering Substances

HIL Interference:

Interfering substances at the levels indicated in the table below were tested in accordance with CLSI Document EP07-A2.

Substance tested	Substance Concentration	U/L	Bias %
Bilirubin (unconjugated)	30 mg/dL	67	-1
Bilirubin (conjugated)	30 mg/dL	61	-6
Lipemia Intralipid®	400 mg/dL	65	0

14.4 Clinical Sensitivity/Specificity/Predictive Values

Detection Capability

The assay is designed to have a limit of blank (LoB) < 8 U/L and a limit of detection (LoD) ≤ 8 U/L. The LoD corresponds to the lowest concentration of aspartate aminotransferase that can be detected with a probability of 95%. The LoD for the

Atellica CH AST assay is 2 U/L, and was determined using 120 determinations, with 60 blank and 60 low level replicates, and a LoB of 1 U/L.

15. SAFETY

Refer to your local and corporate safety manuals and Safety Data Sheet (SDS) for detailed information on safety practices and procedures and a complete description of hazards.

16. RELATED DOCUMENTS

1. Atellica Solution Operating, QC, Calibration and Maintenance procedure
2. Laboratory Quality Control Program
3. QC Schedule for Siemens Atellica Solution
4. Laboratory Safety Manual
5. Safety Data Sheets (SDS)
6. Atellica Solution Limits Chart
7. Quest Diagnostics Records Management Procedure
8. Atellica Solution System Error Messages Chart
9. Centrifuge Use, Maintenance and Function Checks (Lab policy)
10. Specimen Acceptability Requirements (Lab policy)
11. Repeat Testing Requirement (Lab policy)
12. Current Allowable Total Error Specifications at http://questnet1.qdx.com/Business_Groups/Medical/qc/docs/qc_bpt_tea.xls
13. Current package insert of Aspartate Aminotransferase Reagent

17. REFERENCES

1. Ghoshal, Amit K. and Soldin, Steven J., Evaluation of the Dade Behring Dimension[®] RxL: Integrated chemistry system-pediatric reference ranges. Clinica Chimica Acta 2003; 331:144.
2. Package Insert, Aspartate Aminotransferase Reagent, Siemens Healthcare Diagnostics Inc., 08/2020
3. Package Insert, ENZ 2 Calibrator (ENZ 2 CAL), Siemens Healthcare Diagnostics Inc., 07/2019
4. Package Insert, IntelliQ Assayed Multiquel Controls, Bio-Rad Laboratories, 07/2020

18. REVISION HISTORY

Version	Date	Section	Reason	Reviser	Approval

19. ADDENDA

None

Technical SOP

Title	Ammonia (Amm) by Atellica CH Analyzer	
Prepared by	Ashkan Chini	Date: 4/21/2021
Owner	Robert SanLuis	Date: 4/21/2021

Laboratory Approval	Local Effective Date:	
Print Name and Title	Signature	Date
<i>Refer to the electronic signature page for approval and approval dates.</i>		

TABLE OF CONTENTS

1.	Test Information.....	2
2.	Analytical Principle	2
3.	Specimen Requirements.....	2
4.	Reagents	3
5.	Calibrators/Standards	4
6.	Quality Control	5
7.	Equipment And Supplies	7
8.	Procedure	7
9.	Calculations.....	8
10.	Reporting Results And Repeat Criteria.....	8
11.	Expected Values.....	9
12.	Clinical Significance.....	9
13.	Procedure Notes	9
14.	Limitations Of Method	10
15.	Safety	10
16.	Related Documents	10
17.	References.....	11
18.	Revision History	11
19.	Addenda	11

1. TEST INFORMATION

Assay	Method/Instrument	Test Code
Ammonia	Atellica CH Analyzer	NH3

Synonyms/Abbreviations
NH3

Department
Chemistry

2. ANALYTICAL PRINCIPLE

The Atellica CH Amm assay is an enzymatic assay that uses glutamate dehydrogenase (GLDH) and a stabilized NADPH analog. Ammonia reacts with α -ketoglutarate and reduced cofactor to form L-glutamate and the cofactor. The reaction is catalyzed by glutamate dehydrogenase. The decrease in absorbance due to the oxidation of the reduced cofactor is monitored at 340/694 nm and is proportional to the ammonia concentration.

3. SPECIMEN REQUIREMENTS

3.1 Patient Preparation

Component	Special Notations
Fasting/Special Diets	A fasting specimen is preferred.
Specimen Collection and/or Timing	<ul style="list-style-type: none"> • A free-flowing venous (or arterial) blood sample should be collected into specimen tube (preferably pre-chilled). • Do not collect via indwelling catheters or capillary puncture. • Do not collect after physical exercise. • Smoking should be avoided for at least 9 hours before sample collection. The tube should be completely filled and stored tightly capped on ice.
Special Collection Procedures	N/A
Other	N/A

3.2 Specimen Type & Handling

Criteria	
Type	Plasma (Lithium Heparin)
-Preferred	
-Other Acceptable	None

Criteria	
Collection Container	Plasma: Mint green top tube (PST)
Volume - Optimum - Minimum	1.0 mL 0.5 mL
Transport Container and Temperature	Collection container or Plastic vial stored tightly capped on ice.
Stability & Storage Requirements	Room Temperature: Not recommended
	Refrigerated: 2 hours
	Frozen: Not recommended
Timing Considerations	Samples should be analyzed within 30 minutes of centrifugation.
Unacceptable Specimens & Actions to Take	Reject samples that are received greater than 30 minutes after the collection time or are not on ice. Specimens that are unlabeled, improperly labeled, or those that do not meet the stated criteria are unacceptable. Request a recollection and credit the test with the appropriate LIS English text code for “test not performed” message. Examples: Quantity not sufficient-QNS; Wrong collection-UNAC. Document the request for recollection in the LIS.
Compromising Physical Characteristics	Gross hemolysis. Reject sample and request a recollection. Credit the test with the appropriate LIS English text code explanation of HMT (Specimen markedly hemolyzed) Lipemic and icteric samples may generate a flag.
Other Considerations	Before placing on system, ensure samples are free of: <ul style="list-style-type: none"> • Bubbles or foam • Fibrin or other particulate matter Concentrations may more than double in plasma when stored at room temperature for 6 hours.

NOTE: Labeling requirements for all reagents, calibrators and controls include: (1) Open date, (2) Substance name, (3) Lot number, (4) Date of preparation, (5) Expiration date, (6) Initials of tech, and (7) Any special storage instructions. Check all for visible signs of degradation. When placed onboard the analyzer, the instrument captures the date / time loaded and calculates and tracks the opened expiration.

4. REAGENTS

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

4.1 Reagent Summary

Reagents	Supplier & Catalog Number
Ammonia (Amm)	Siemens, Atellica CH, Cat. No. 11097529

4.2 Reagent Preparation and Storage

Reagent	Ammonia (Amm)
Storage	Store at 2-8°C
Stability	Onboard per well: 30 days
Preparation	Reagent is liquid and ready to use.

5. CALIBRATORS/STANDARDS

5.1 Calibrators/Standards Used

Calibrator	Supplier and Catalog Number
CHEM III Calibrator (CHEM III CAL)	Siemens Atellica CH , Cat. No. 11099335

5.2 Calibrator Preparation and Storage

Calibrator	CHEM III Calibrator (CHEM III CAL)
Preparation	Liquid and ready to use.
Storage/Stability	<ul style="list-style-type: none"> • Store at 2-8°C • Unopened: stable until expiration date stamped on the box. • Opened: stable for 30 days when recapped immediately after use.

5.3 Calibration Parameter

Criteria	Special Notations
Reference Material	CHEM III Calibrator (CHEM III CAL)
Assay Range	See Package Insert for specific assay ranges.
Suggested Calibration Level	See Reagent Package Insert for lot specific assigned values in $\mu\text{mol/L}$
Frequency	<ul style="list-style-type: none"> • When changing lot numbers of primary reagent packs. • At the end of the lot calibration interval (30 days), for a specified lot of calibrated reagent on the system. • At the end of pack calibration interval (3 days), for calibrated reagent packs on the system. • When indicated by quality control results. • After major maintenance or service. <p>At the end of the onboard stability interval, replace the reagent pack on the system with a new reagent pack. Recalibration is not required, unless the lot calibration interval is exceeded.</p>

Calibration Scheme	See Package Insert for specific calibration scheme.
Procedure	Refer to the Atellica Solution Operating, QC, Calibration and Maintenance procedure for specific instructions.

5.4 Tolerance Limits

IF.....	THEN.....
If result fall within assay-specific specification, and QC values are within acceptable limits,	proceed with analysis
If result falls outside assay-specific specification, or QC values are out of Acceptable limits,	troubleshoot the assay and/or instrument and repeat calibration

6. QUALITY CONTROL

6.1 Controls Used

Controls	Supplier and Catalog Number
InteliQ Ethanol/Ammonia Control, levels 1, 2 & 3	Bio-Rad Laboratories Cat. No. 12008299, 12008300, 12008301

6.2 Control Preparation and Storage

Control	InteliQ Ethanol/Ammonia Control, levels 1, 2 & 3
Preparation	Before use gently invert to ensure homogeneity
Storage/Stability	Unopened: until expiration date at 2-8C Opened, off-board: 4 days at 2-8C (ETOH is 3 days) Opened, on-board: 13 days at 2-8C (ETOH is 3 days) Note: Product can only be used as instrument storage or refrigerator storage, but NOT a combination of both.

6.3 Frequency

Analyze all levels of QC material after every calibration and each day of testing (notated on the QC frequency sheets posted on the instruments).

Refer to the Siemens Atellica QC Schedule and the Siemens Atellica Quick Reference Guide.

6.4 Tolerance Limits and Criteria for Acceptable QC

Step	Action
1	Acceptable ranges for QC are programmed into the instrument’s Quality Control software system and Unity Real Time, and may be posted near the instrument for use during computer downtime.

Step	Action
2	<p>Run Rejection Criteria</p> <ul style="list-style-type: none"> Anytime the established parameters are exceeded (if one QC result exceeds 2 SD), the run is considered out of control (failed) and patient results must not be reported. The technologist must follow the procedure in the Laboratory QC Program to resolve the problem.
3	<p>Corrective Action:</p> <ul style="list-style-type: none"> All rejected runs must be effectively addressed through corrective action. Steps taken in response to QC failures must be documented. Patient samples in failed analytical runs must be <u>reanalyzed according to the Laboratory QC Program</u>. Supervisors may override rejection of partial or complete runs only with detailed documentation and criteria for overrides that are approved by the Medical Director. Consult corrective action guidelines in Laboratory QC Program. Follow corrective action guidelines in the Laboratory QC Program. Corrective action documentation must follow the Laboratory Quality Control Program.
4	<p>Review of QC</p> <ul style="list-style-type: none"> QC must be reviewed weekly by the Group Lead or designee and monthly by the Supervisor/Manager or designee. If the SD and/or CV are greater than established ranges, investigate the cause for the imprecision and document implementation of corrective actions.

6.5 Documentation

- QC tolerance limits are programmed into the instrument and Unity Real Time; it calculates cumulative mean, SD and CV and stores all information for easy retrieval.
- Quality control records are reviewed daily at the bench, weekly by the Group Lead or designee, and monthly by the Supervisor/Manager or designee.
- Refer to complete policies and procedures for QC documentation and for record retention requirements in the Laboratory QC Program.

6.6 Quality Assurance Program

- Each new lot number of reagent or new shipment of the same lot of reagent must be tested with external control materials and previously analyzed samples. Performance of the new lot must be equivalent to the previous lot; utilize published TEA for acceptability criteria.
- Training must be successfully completed and documented prior to performing this test. This procedure must be incorporated into the departmental competency assessment program.

- The laboratory participates in CAP proficiency testing. All proficiency testing materials must be treated in the same manner as patient samples.
- Monthly QC must be presented to the Medical Director or designee for review and signature.
- Monthly QC mean and SD are sent to Bio-Rad Laboratories for peer group comparison.
- Consult the Laboratory QC Program for complete details.

7. EQUIPMENT and SUPPLIES

7.1 Assay Platform

Siemens Atellica CH Analyzer

7.2 Equipment

- Refrigerator capable of sustaining 2–8°C.
- Freezer capable of sustaining range not to exceed -20 to -50°C.
- Centrifuge

7.3 Supplies

- System Fluids
- Assorted calibrated pipettes (MLA or equivalent) and disposable tips

8. PROCEDURE

Atellica CH Ammonia (Amm) is required to perform this test.

Ammonia is performed on the Atellica CH Analyzer after the method is calibrated and Quality Controls are acceptable.

NOTE: For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

8.1	Instrument Set-up Protocol
1.	Perform any required instrument maintenance.
2.	Ensure that the instrument has sufficient primary and ancillary reagents.
3.	Check status of cuvettes and tips. Check waste levels. Fill or empty as appropriate.
4.	Check calibration status and re-calibrate as needed.

8.2	Specimen Testing
1.	Centrifuge the specimens.

8.2	Specimen Testing
2.	Load the sample in the Atellica rack and place the rack into the Sample Handler to initiate testing. **NOTE: If not equipped with an in-line decapper unit, samples must be de-capped prior to loading on the Atellica system
3.	Refer to the general operating procedure for detailed steps.
4.	Follow protocol in section 10.6 “Repeat Criteria and Resulting” for samples with results above the analytical measurement range (AMR). Investigate any flagged results and repeat as necessary.
5.	Append the appropriate English text code qualifier messages to any samples requiring a comment regarding sample quality and/or any other pertinent factors.

NOTE: In the event that the test system becomes inoperable, notify supervision or designee for further direction. Patient specimens must be stored in a manner that maintains the integrity of the specimen.

9. CALCULATIONS

The instrument automatically calculates the concentration of Ammonia in $\mu\text{mol/L}$.

10. REPORTING RESULTS AND REPEAT CRITERIA

10.1 Interpretation of Data

None required

10.2 Rounding

No rounding is necessary. Instrument reports results as a whole number.

10.3 Units of Measure

$\mu\text{mol/L}$

10.4 Clinically Reportable Range (CRR)

10 – 1499 $\mu\text{mol/L}$

10.5 Review Patient Data

Each result is reviewed for error messages. Resolve any problems noted before issuing patient reports.

10.6 Repeat Criteria and Resulting

All repeats must replicate the original result within the total allowable error (TEa) of the assay. Refer to TEa listing for specific information.

Values that fall below or within the AMR or CRR may be reported without repeat.
 Values that exceed the upper ranges must be repeated.

IF the result is ...	THEN...
< 10 µmol/L	Assure there is sufficient sample devoid of bubbles, cellular debris, and/or fibrin clots. Report as: < 10 µmol/L
≥ 750 µmol/L	On Board Automated Dilution: Results ≥ 750 µmol/L will automatically have repeat testing performed into the instrument using dilution factor of 2. No multiplication is necessary.
> 1499 µmol/L	If the recommended dilution does not give results within the clinically reportable range, report as: "> 1499 µmol/L -REP" Bring to the attention of Tech in Charge (TIC) or Group Lead to check for integrity issues prior to release of results.

Message	Code
Verified by repeat analysis	Append -REP to the result.

11. EXPECTED VALUES

11.1 Reference Ranges

11 – 32 µmol/L

11.2 Critical Values

> 199 µmol/L

11.3 Standard Required Messages

None established

12. CLINICAL SIGNIFICANCE

The major source of circulating ammonia is the gastrointestinal (GI) tract. Under normal conditions, ammonia is metabolized to urea by liver enzymes. Several diseases, both inherited and acquired, cause elevated ammonia (hyperammonemia). The inherited deficiencies of urea cycle enzymes are the major cause of hyperammonemia in infants. Acquired hyperammonemia most often results from liver disease, renal failure, and Reye's syndrome. Elevated ammonia is toxic to the central nervous system.

13. PROCEDURE NOTES

- **FDA Status:** FDA Approved/cleared
- **Validated Test Modifications:** None

The instrument reporting system contains error messages to warn the operator of specific malfunctions. Any report slip containing such error messages should be held for follow-up.

14. LIMITATIONS OF METHOD

14.1 Analytical Measurement Range (AMR)

10 – 750 $\mu\text{mol/L}$

14.2 Precision

Material	Mean $\mu\text{mol/L}$	Standard Deviation (%CV)	
		Repeatability	Within-Lab
Plasma QC	48	2.9	6.2
Plasma QC	61	2.9	4.7
Plasma QC	197	4.1	2.1
Plasma Pool	1050	4.4	0.4

14.3 Interfering Substances

HIL Interference:

Interfering substances at the levels indicated in the table below were tested in accordance with CLSI Document EP07-A2.

Substance tested	Substance Concentration	$\mu\text{mol/L}$	Bias %
Hemoglobin	75 mg/dL	81	9
Bilirubin (conjugated)	20 mg/dL	78	-9
Bilirubin (unconjugated)	20 mg/dL	78	-9
Lipemia Intralipid®	200 mg/dL	83	-5

Lithium heparin at concentrations found in blood collection tubes do not interfere with this method.

Lipemic and icteric samples may generate a flag. Do not clear lipemia in samples that generate a flag as the results may be invalid.

14.4 Clinical Sensitivity/Specificity/Predictive Values

Detection Capability

The assay is designed to have a limit of blank (LoB) < limit of detection (LoD) and $\text{LoD} \leq 6 \mu\text{mol/L}$, and a limit of quantitation (LoQ) $\leq 10 \mu\text{mol/L}$. The LoD for the Atellica CH Amm assay is $6 \mu\text{mol/L}$, and a LoB of $2 \mu\text{mol/L}$. The LoQ of the Atellica CH Amm assay is $10 \mu\text{mol/L}$.

15. SAFETY

Refer to your local and corporate safety manuals and Safety Data Sheet (SDS) for detailed information on safety practices and procedures and a complete description of hazards.

Chem III CAL may cause an allergic skin reaction. Wear protective gloves/clothing and eye/face protection. IF ON SKIN: wash with plenty of soap and water. If irritation or rash occurs, get medical attention. **Contains:** reaction mass of 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-2H-isothiazol-3-one (3:1)

16. RELATED DOCUMENTS

1. Atellica Solution Operating, QC, Calibration and Maintenance procedure
2. Laboratory Quality Control Program
3. QC Schedule for Siemens Atellica Solution
4. Laboratory Safety Manual
5. Safety Data Sheets (SDS)
6. Atellica Solution Limits Chart
7. Quest Diagnostics Records Management Procedure
8. Atellica Solution System Error Messages Chart
9. Centrifuge Use, Maintenance and Function Checks (Lab policy)
10. Specimen Acceptability Requirements (Lab policy)
11. Repeat Testing Requirement (Lab policy)
12. Current Allowable Total Error Specifications at http://questnet1.qdx.com/Business_Groups/Medical/qc/docs/qc_bpt_tea.xls
13. Current package insert of Ammonia Reagent

17. REFERENCES

1. Package Insert, Ammonia Reagent, Siemens Healthcare Diagnostics Inc., 03/2020
2. Package Insert, CHEM III Calibrator, Siemens Healthcare Diagnostics Inc., 07/2019
3. Package Insert, IntelliQ Ethanol/Ammonia Controls, Bio-Rad Laboratories, 11/2020

18. REVISION HISTORY

Version	Date	Section	Reason	Reviser	Approval

19. ADDENDA

None

Technical SOP

Title	Amylase (AMY-2) by Atellica CH Analyzer	
Prepared by	Ashkan Chini	Date: 4/21/2021
Owner	Robert SanLuis	Date: 4/21/2021

Laboratory Approval	Local Effective Date:	
Print Name and Title	Signature	Date
<i>Refer to the electronic signature page for approval and approval dates.</i>		

TABLE OF CONTENTS

1.	Test Information.....	2
2.	Analytical Principle	2
3.	Specimen Requirements.....	2
4.	Reagents	3
5.	Calibrators/Standards	4
6.	Quality Control	5
7.	Equipment And Supplies	7
8.	Procedure	7
9.	Calculations.....	8
10.	Reporting Results And Repeat Criteria.....	8
11.	Expected Values.....	9
12.	Clinical Significance.....	9
13.	Procedure Notes	9
14.	Limitations Of Method	10
15.	Safety	10
16.	Related Documents	10
17.	References.....	11
18.	Revision History	11
19.	Addenda	11

1. TEST INFORMATION

Assay	Method/Instrument	Test Code
Amylase	Atellica CH Analyzer	AMYL

Synonyms/Abbreviations
AMY

Department
Chemistry

2. ANALYTICAL PRINCIPLE

The Atellica CH AMY-2 assay uses ethylidene blocked *p*-nitrophenyl-maltoheptaoside as substrate. The indicator enzyme α -glucosidase, used to release *p*-nitrophenol (PNP), is also employed in the assay. The terminal glucose of the substrate is chemically blocked, preventing cleavage by the indicator enzymes. The released *p*-nitrophenol is measured at 410/694 nm.

3. SPECIMEN REQUIREMENTS

3.1 Patient Preparation

Component	Special Notations
Fasting/Special Diets	N/A
Specimen Collection and/or Timing	Normal procedures for collecting and storing serum and plasma may be used for samples to be analyzed by this method.
Special Collection Procedures	N/A
Other	N/A

3.2 Specimen Type & Handling

Criteria	
Type -Preferred -Other Acceptable	Plasma (Lithium Heparin) Serum
Collection Container	Plasma: Mint green top tube (PST) Serum: Red top tube, Serum separator tube (SST)
Volume - Optimum - Minimum	1.0 mL 0.5 mL

Criteria	
Transport Container and Temperature	Collection container or Plastic vial at room temperature
Stability & Storage Requirements	Room Temperature: 8 days
	Refrigerated: 31 days
	Frozen: 1 year
Timing Considerations	N/A
Unacceptable Specimens & Actions to Take	Specimens that are unlabeled, improperly labeled, or those that do not meet the stated criteria are unacceptable. Request a recollection and credit the test with the appropriate LIS English text code for “test not performed” message. Examples: Quantity not sufficient-QNS; Wrong collection-UNAC. Document the request for recollection in the LIS.
Compromising Physical Characteristics	Gross hemolysis. Reject sample and request a recollection. Credit the test with the appropriate LIS English text code explanation of HMT (Specimen markedly hemolyzed)
Other Considerations	Allow Red Top or SST to clot completely prior to centrifugation. Before placing on system, ensure samples are free of: <ul style="list-style-type: none"> • Bubbles or foam • Fibrin or other particulate matter

NOTE: Labeling requirements for all reagents, calibrators and controls include: (1) Open date, (2) Substance name, (3) Lot number, (4) Date of preparation, (5) Expiration date, (6) Initials of tech, and (7) Any special storage instructions. Check all for visible signs of degradation. When placed onboard the analyzer, the instrument captures the date / time loaded and calculates and tracks the opened expiration.

4. REAGENTS

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

4.1 Reagent Summary

Reagents	Supplier & Catalog Number
Amylase-2 (AMY-2)	Siemens, Atellica CH, Cat. No. 11097649

4.2 Reagent Preparation and Storage

Reagent	Amylase-2 (AMY-2)
Storage	Store at 2-8°C
Stability	Onboard per well: 31 days
Preparation	Reagent is liquid and ready to use.

5. CALIBRATORS/STANDARDS

5.1 Calibrators/Standards Used

Calibrator	Supplier and Catalog Number
Special Chemistry Calibrator (SPCL CHEM CAL)	Siemens Atellica CH, Cat. No. 11099438

5.2 Calibrator Preparation and Storage

Calibrator	Special Chemistry Calibrator (SPCL CHEM CAL)
Preparation	<ol style="list-style-type: none"> 1. Open each vial carefully. 2. Add 5.0 mL of reagent grade water into each vial using a calibrated pipette. Replace rubber stopper. 3. Let the vials stand for 30 minutes at room temperature to allow the lyophilized material to dissolve. 4. Prior to use, to ensure homogeneity and to avoid foam formation, mix the contents by gently inverting the vials.
Storage/Stability	<ul style="list-style-type: none"> • Store at 2-8°C • Unopened: until expiration date stamped on the box • Reconstituted: stable for 7 days

5.3 Calibration Parameter

Criteria	Special Notations
Reference Material	Special Chemistry Calibrator (SPCL CHEM CAL)
Assay Range	See Package Insert for specific assay ranges.
Suggested Calibration Level	See Reagent Package Insert for lot specific assigned values in U/L
Frequency	<ul style="list-style-type: none"> • When changing lot numbers of primary reagent packs. • At the end of the lot calibration interval (62 days), for a specified lot of calibrated reagent on the system. • At the end of pack calibration interval (31 days), for calibrated reagent packs on the system. • When indicated by quality control results. • After major maintenance or service. <p>At the end of the onboard stability interval, replace the reagent pack on the system with a new reagent pack. Recalibration is not required, unless the lot calibration interval is exceeded.</p>
Calibration Scheme	See Package Insert for specific calibration scheme.
Procedure	Refer to the Atellica Solution Operating, QC, Calibration and Maintenance procedure for specific instructions.

5.4 Tolerance Limits

IF.....	THEN.....
If result fall within assay-specific specification, and QC values are within acceptable limits,	proceed with analysis
If result falls outside assay-specific specification, or QC values are out of Acceptable limits,	troubleshoot the assay and/or instrument and repeat calibration

6. QUALITY CONTROL

6.1 Controls Used

Controls	Supplier and Catalog Number
InteliQ Assayed Multiquel Control Levels 1 & 3	Bio-Rad Laboratories Cat. No. 12008256, 12008258

6.2 Control Preparation and Storage

Control	InteliQ Assayed Multiquel Control Levels 1 & 3
Preparation	Allow to stand at room temperature (18-25C) until completely thawed but not more than one (1) hour. Once thawed, gently invert several times to ensure homogeneity.
Storage/Stability	Frozen: until the expiration date if unopened at -20 to -70C Thawed and Unopened: 30 days at 2-8C for Amylase Thawed and Opened: 14 days at 2-8C for Amylase Note: stability varies by assay

6.3 Frequency

Analyze all levels of QC material after every calibration and each day of testing (notated on the QC frequency sheets posted on the instruments).

Refer to the Siemens Atellica QC Schedule and the Siemens Atellica Quick Reference Guide.

6.4 Tolerance Limits and Criteria for Acceptable QC

Step	Action
1	Acceptable ranges for QC are programmed into the instrument's Quality Control software system and Unity Real Time, and may be posted near the instrument for use during computer downtime.
2	Run Rejection Criteria <ul style="list-style-type: none"> Anytime the established parameters are exceeded (if one QC result exceeds 2 SD), the run is considered out of control (failed) and patient results must not be reported.

Step	Action
	<ul style="list-style-type: none"> The technologist must follow the procedure in the Laboratory QC Program to resolve the problem.
3	<p>Corrective Action:</p> <ul style="list-style-type: none"> All rejected runs must be effectively addressed through corrective action. Steps taken in response to QC failures must be documented. Patient samples in failed analytical runs must be <u>reanalyzed according to the Laboratory QC Program</u>. Supervisors may override rejection of partial or complete runs only with detailed documentation and criteria for overrides that are approved by the Medical Director. Consult corrective action guidelines in Laboratory QC Program. Follow corrective action guidelines in the Laboratory QC Program. Corrective action documentation must follow the Laboratory Quality Control Program.
4	<p>Review of QC</p> <ul style="list-style-type: none"> QC must be reviewed weekly by the Group Lead or designee and monthly by the Supervisor/Manager or designee. If the SD and/or CV are greater than established ranges, investigate the cause for the imprecision and document implementation of corrective actions.

6.5 Documentation

- QC tolerance limits are programmed into the instrument and Unity Real Time; it calculates cumulative mean, SD and CV and stores all information for easy retrieval.
- Quality control records are reviewed daily at the bench, weekly by the Group Lead or designee, and monthly by the Supervisor/Manager or designee.
- Refer to complete policies and procedures for QC documentation and for record retention requirements in the Laboratory QC Program.

6.6 Quality Assurance Program

- Each new lot number of reagent or new shipment of the same lot of reagent must be tested with external control materials and previously analyzed samples. Performance of the new lot must be equivalent to the previous lot; utilize published TEA for acceptability criteria.
- Training must be successfully completed and documented prior to performing this test. This procedure must be incorporated into the departmental competency assessment program.
- The laboratory participates in CAP proficiency testing. All proficiency testing materials must be treated in the same manner as patient samples.
- Monthly QC must be presented to the Medical Director or designee for review and signature.

- Monthly QC mean and SD are sent to Bio-Rad Laboratories for peer group comparison.
- Consult the Laboratory QC Program for complete details.

7. EQUIPMENT and SUPPLIES

7.1 Assay Platform

Siemens Atellica CH Analyzer

7.2 Equipment

- Refrigerator capable of sustaining 2–8°C.
- Freezer capable of sustaining range not to exceed -20 to -70°C.
- Centrifuge

7.3 Supplies

- System Fluids
- Assorted calibrated pipettes (MLA or equivalent) and disposable tips

8. PROCEDURE

Atellica CH Amylase-2 (AMY-2) is required to perform this test.

Amylase is performed on the Atellica CH Analyzer after the method is calibrated and Quality Controls are acceptable.

NOTE: For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

8.1	Instrument Set-up Protocol
1.	Perform any required instrument maintenance.
2.	Ensure that the instrument has sufficient primary and ancillary reagents.
3.	Check status of cuvettes and tips. Check waste levels. Fill or empty as appropriate.
4.	Check calibration status and re-calibrate as needed.

8.2	Specimen Testing
1.	Centrifuge the specimens.
2.	Load the sample in the Atellica rack and place the rack into the Sample Handler to initiate testing. **NOTE: If not equipped with an in-line decapper unit, samples must be de-capped prior to loading on the Atellica system
3.	Refer to the general operating procedure for detailed steps.

8.2	Specimen Testing
4.	Follow protocol in section 10.6 “Repeat Criteria and Resulting” for samples with results above the analytical measurement range (AMR). Investigate any flagged results and repeat as necessary.
5.	Append the appropriate English text code qualifier messages to any samples requiring a comment regarding sample quality and/or any other pertinent factors.

NOTE: In the event that the test system becomes inoperable, notify supervision or designee for further direction. Patient specimens must be stored in a manner that maintains the integrity of the specimen.

9. CALCULATIONS

The instrument automatically calculates the concentration of Amylase in U/L.

10. REPORTING RESULTS AND REPEAT CRITERIA

10.1 Interpretation of Data

None required

10.2 Rounding

No rounding is necessary. Instrument reports results as a whole number.

10.3 Units of Measure

U/L

10.4 Clinically Reportable Range (CRR)

20 – 4500 U/L

10.5 Review Patient Data

Each result is reviewed for error messages. Resolve any problems noted before issuing patient reports.

10.6 Repeat Criteria and Resulting

All repeats must replicate the original result within the total allowable error (TEa) of the assay. Refer to TEa listing for specific information.

Values that fall below or within the AMR or CRR may be reported without repeat.
Values that exceed the upper ranges must be repeated.

IF the result is ...	THEN...
< 20 U/L	Assure there is sufficient sample devoid of bubbles, cellular debris, and/or fibrin clots. Report as: < 20 U/L
≥ 1500 U/L	On Board Automated Dilution: Results ≥ 1500 U/L will automatically have repeat testing performed into the instrument using dilution factor of 3. No multiplication is necessary.
> 4500 U/L	If the recommended dilution does not give results within the clinically reportable range, report as: “> 4500 U/L -REP” Bring to the attention of Tech in Charge (TIC) or Group Lead to check for integrity issues prior to release of results.

Message	Code
Verified by repeat analysis	Append -REP to the result.

11. EXPECTED VALUES

11.1 Reference Ranges

Age	Male/Female
Adult (>17 years):	25 - 115 U/L
Pediatric:	
1 – 17 years	0 - 105
6 – 11 months	0 - 80
31 – 183 days	0 - 42
0 – 30 days	0 - 17

11.2 Critical Values

None established

11.3 Standard Required Messages

None established

12. CLINICAL SIGNIFICANCE

Amylase measurements are used primarily for the diagnosis and treatment of pancreatitis.

13. PROCEDURE NOTES

- **FDA Status:** FDA Approved/cleared
- **Validated Test Modifications:** None

The instrument reporting system contains error messages to warn the operator of specific malfunctions. Any report slip containing such error messages should be held for follow-up.

14. LIMITATIONS OF METHOD

14.1 Analytical Measurement Range (AMR)

20 – 1500 U/L

14.2 Precision

Material	Mean U/L	Standard Deviation (%CV)	
		Repeatability	Within-Lab
Sample 1	52	0.6	1.4
Serum QC	187	0.8	0.6
Sample 2	1128	2.2	0.4

14.3 Interfering Substances

HIL Interference:

Interfering substances at the levels indicated in the table below were tested in accordance with CLSI Document EP07-A2.

Substance tested	Substance Concentration	U/L	Bias %
Hemoglobin	500 mg/dL	100	-1
Bilirubin (unconjugated)	30 mg/dL	105	-6
Bilirubin (conjugated)	30 mg/dL	105	-9
Lipemia Intralipid®	650 mg/dL	102	3

14.4 Clinical Sensitivity/Specificity/Predictive Values

Detection Capability

The assay is designed to have a limit of blank (LoB) \leq limit of detection (LoD), LoD \leq limit of quantitation (LoQ), and LoQ \leq 20 U/L for serum and plasma.

The LoD corresponds to the lowest concentration of amylase that can be detected with a probability of 95%. The LoD for the Atellica CH AMY-2 assay is 7 U/L for serum and plasma, and was determined using 480 determinations, with 240 blank and 240 low level replicates, and a LoB of 1 U/L for serum and plasma. The LoQ for the Atellica CH AMY-2 assay is 20 U/L for serum and plasma. This is the lowest amount of analyte in a sample that can be accurately quantitated with a total allowable error \leq 30%.

15. SAFETY

Refer to your local and corporate safety manuals and Safety Data Sheet (SDS) for detailed information on safety practices and procedures and a complete description of hazards.

16. RELATED DOCUMENTS

1. Atellica Solution Operating, QC, Calibration and Maintenance procedure
2. Laboratory Quality Control Program
3. QC Schedule for Siemens Atellica Solution
4. Laboratory Safety Manual
5. Safety Data Sheets (SDS)
6. Atellica Solution Limits Chart
7. Quest Diagnostics Records Management Procedure
8. Atellica Solution System Error Messages Chart
9. Centrifuge Use, Maintenance and Function Checks (Lab policy)
10. Specimen Acceptability Requirements (Lab policy)
11. Repeat Testing Requirement (Lab policy)
12. Current Allowable Total Error Specifications at http://questnet1.qdx.com/Business_Groups/Medical/qc/docs/qc_bpt_tea.xls
13. Current package insert of Amylase-2 Reagent

17. REFERENCES

1. Ghoshal, Amit K. and Soldin, Steven J., Evaluation of the Dade Behring Dimension[®] RxL: Integrated chemistry system-pediatric reference ranges. Clinica Chimica Acta 2003; 331:144.
2. Package Insert, Amylase-2 Reagent, Siemens Healthcare Diagnostics Inc., 08/2019.
3. Package Insert, Special Chemistry Calibrator (SPCL CHEM CAL), Siemens Healthcare Diagnostics Inc., 10/2019.
4. Package Insert, InteliQ Assayed Multiqual Controls, Bio-Rad Laboratories, 07/2020

18. REVISION HISTORY

Version	Date	Section	Reason	Reviser	Approval

19. ADDENDA

None

Technical SOP

Title	Alkaline Phosphatase (ALP-2c) by Atellica CH Analyzer	
Prepared by	Ashkan Chini	Date: 4/21/2021
Owner	Robert SanLuis	Date: 4/21/2021

Laboratory Approval	Local Effective Date:	
Print Name and Title	Signature	Date
<i>Refer to the electronic signature page for approval and approval dates.</i>		

TABLE OF CONTENTS

1.	Test Information.....	2
2.	Analytical Principle	2
3.	Specimen Requirements.....	2
4.	Reagents	3
5.	Calibrators/Standards	4
6.	Quality Control	5
7.	Equipment And Supplies	7
8.	Procedure	7
9.	Calculations.....	8
10.	Reporting Results And Repeat Criteria.....	8
11.	Expected Values.....	9
12.	Clinical Significance.....	10
13.	Procedure Notes	10
14.	Limitations Of Method	10
15.	Safety	11
16.	Related Documents	11
17.	References.....	11
18.	Revision History	12
19.	Addenda	12

1. TEST INFORMATION

Assay	Method/Instrument	Test Code
Alkaline Phosphatase	Atellica CH Analyzer	ALKPH

Synonyms/Abbreviations
Alk Phos, ALP

Department
Chemistry

2. ANALYTICAL PRINCIPLE

Alkaline phosphatase catalyzes the transphosphorylation of *p*-nitrophenylphosphate (*p*-NPP) to *p*-nitrophenol (*p*-NP) in the presence of the transphosphorylating buffer, 2-amino-2-methyl-1-propanol (AMP). The reaction is enhanced through the use of magnesium and zinc ions. The change in absorbance at 410 nm due to the formation of *p*-NP is directly proportional to the Atellica CH Alkaline Phosphatase, Concentrated (ALP-2c) activity, since other reactants are present in non-rate limiting quantities. The change is measured using a bichromatic (410/478 nm) rate technique.

3. SPECIMEN REQUIREMENTS

3.1 Patient Preparation

Component	Special Notations
Fasting/Special Diets	N/A
Specimen Collection and/or Timing	Normal procedures for collecting and storing serum and plasma may be used for samples to be analyzed by this method.
Special Collection Procedures	N/A
Other	N/A

3.2 Specimen Type & Handling

Criteria	
Type	Plasma (Lithium Heparin)
-Preferred	
-Other Acceptable	Serum

Criteria	
Collection Container	Plasma: Mint green top tube (PST) Serum: Red top tube, Serum separator tube (SST)
Volume - Optimum - Minimum	1.0 mL 0.5 mL
Transport Container and Temperature	Collection container or Plastic vial at room temperature
Stability & Storage Requirements	Room Temperature: 8 hours
	Refrigerated: 7 days
	Frozen: 6 months
Timing Considerations	N/A
Unacceptable Specimens & Actions to Take	Specimens that are unlabeled, improperly labeled, or those that do not meet the stated criteria are unacceptable. Request a recollection and credit the test with the appropriate LIS English text code for “test not performed” message. Examples: Quantity not sufficient-QNS; Wrong collection-UNAC. Document the request for recollection in the LIS.
Compromising Physical Characteristics	Gross hemolysis. Reject sample and request a recollection. Credit the test with the appropriate LIS English text code explanation of HMT (Specimen markedly hemolyzed)
Other Considerations	Allow Red Top or SST to clot completely prior to centrifugation. Before placing on system, ensure samples are free of: <ul style="list-style-type: none"> • Bubbles or foam • Fibrin or other particulate matter

NOTE: Labeling requirements for all reagents, calibrators and controls include: (1) Open date, (2) Substance name, (3) Lot number, (4) Date of preparation, (5) Expiration date, (6) Initials of tech, and (7) Any special storage instructions. Check all for visible signs of degradation. When placed onboard the analyzer, the instrument captures the date / time loaded and calculates and tracks the opened expiration.

4. REAGENTS

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

4.1 Reagent Summary

Reagents	Supplier & Catalog Number
Alkaline Phosphatase, Concentrated (ALP-2c)	Siemens, Atellica CH, Cat. No. 11097600

4.2 Reagent Preparation and Storage

Reagent	Alkaline Phosphatase, Concentrated (ALP-2c)
Storage	<ul style="list-style-type: none"> • Store at 2-8°C • Protect from light sources
Stability	Onboard per well: 30 days
Preparation	Reagent is liquid and ready to use.

5. CALIBRATORS/STANDARDS

5.1 Calibrators/Standards Used

Calibrator	Supplier and Catalog Number
Alkaline Phosphatase-2 Calibrator (ALP-2 CAL)	Siemens Atellica CH, Cat. No. 11099316

5.2 Calibrator Preparation and Storage

Calibrator	Alkaline Phosphatase-2 Calibrator (ALP-2 CAL)
Preparation	Calibrators are liquid and ready to use.
Storage/Stability	<ul style="list-style-type: none"> • Store at 2-8°C • Unopened: stable until expiration date stamped on the box. • Opened: remains stable for 30 days when recapped immediately after use.

5.3 Calibration Parameter

Criteria	Special Notations
Reference Material	Alkaline Phosphatase-2 Calibrator (ALP-2 CAL)
Assay Range	See Package Insert for specific assay ranges.
Suggested Calibration Level	See Reagent Package Insert for lot specific assigned values in U/L
Frequency	<ul style="list-style-type: none"> • When changing lot numbers of primary reagent packs. • At the end of the lot calibration interval (60 days), for a specified lot of calibrated reagent on the system. • At the end of pack calibration interval (17 days), for calibrated reagent packs on the system. • When indicated by quality control results. • After major maintenance or service. <p>At the end of the onboard stability interval, replace the reagent pack on the system with a new reagent pack.</p>

	Recalibration is not required, unless the lot calibration interval is exceeded.
Calibration Scheme	See Package Insert for specific calibration scheme.
Procedure	Refer to the Atellica Solution Operating, QC, Calibration and Maintenance procedure for specific instructions.

5.4 Tolerance Limits

IF.....	THEN.....
If result fall within assay-specific specification, and QC values are within acceptable limits,	proceed with analysis
If result falls outside assay-specific specification, or QC values are out of Acceptable limits,	troubleshoot the assay and/or instrument and repeat calibration

6. QUALITY CONTROL

6.1 Controls Used

Controls	Supplier and Catalog Number
InteliQ Assayed Multiquel Control Levels 1 & 3	Bio-Rad Laboratories Cat. No. 12008256, 12008258

6.2 Control Preparation and Storage

Control	InteliQ Assayed Multiquel Control Levels 1 & 3
Preparation	Allow to stand at room temperature (18-25C) until completely thawed but not more than one (1) hour. Once thawed, gently invert several times to ensure homogeneity.
Storage/Stability	Frozen: until the expiration date if unopened at -20 to -70C Thawed and Unopened: 30 days at 2-8C for ALP Thawed and Opened: 9 days at 2-8C for ALP Note: stability varies by assay

6.3 Frequency

Analyze all levels of QC material after every calibration and each day of testing (notated on the QC frequency sheets posted on the instruments).

Refer to the Siemens Atellica QC Schedule and the Siemens Atellica Quick Reference Guide.

6.4 Tolerance Limits and Criteria for Acceptable QC

Step	Action
1	Acceptable ranges for QC are programmed into the instrument's Quality Control software system and Unity Real Time, and may be posted near the instrument for use during computer downtime.
2	<p>Run Rejection Criteria</p> <ul style="list-style-type: none"> Anytime the established parameters are exceeded (if one QC result exceeds 2 SD), the run is considered out of control (failed) and patient results must not be reported. The technologist must follow the procedure in the Laboratory QC Program to resolve the problem.
3	<p>Corrective Action:</p> <ul style="list-style-type: none"> All rejected runs must be effectively addressed through corrective action. Steps taken in response to QC failures must be documented. Patient samples in failed analytical runs must be <u>reanalyzed according to the Laboratory QC Program</u>. Supervisors may override rejection of partial or complete runs only with detailed documentation and criteria for overrides that are approved by the Medical Director. Consult corrective action guidelines in Laboratory QC Program. Follow corrective action guidelines in the Laboratory QC Program. Corrective action documentation must follow the Laboratory Quality Control Program.
4	<p>Review of QC</p> <ul style="list-style-type: none"> QC must be reviewed weekly by the Group Lead or designee and monthly by the Supervisor/Manager or designee. If the SD and/or CV are greater than established ranges, investigate the cause for the imprecision and document implementation of corrective actions.

6.5 Documentation

- QC tolerance limits are programmed into the instrument and Unity Real Time; it calculates cumulative mean, SD and CV and stores all information for easy retrieval.
- Quality control records are reviewed daily at the bench, weekly by the Group Lead or designee, and monthly by the Supervisor/Manager or designee.
- Refer to complete policies and procedures for QC documentation and for record retention requirements in the Laboratory QC Program.

6.6 Quality Assurance Program

- Each new lot number of reagent or new shipment of the same lot of reagent must be tested with external control materials and previously analyzed samples.

Performance of the new lot must be equivalent to the previous lot; utilize published TEA for acceptability criteria.

- Training must be successfully completed and documented prior to performing this test. This procedure must be incorporated into the departmental competency assessment program.
- The laboratory participates in CAP proficiency testing. All proficiency testing materials must be treated in the same manner as patient samples.
- Monthly QC must be presented to the Medical Director or designee for review and signature.
- Monthly QC mean and SD are sent to Bio-Rad Laboratories for peer group comparison.
- Consult the Laboratory QC Program for complete details.

7. EQUIPMENT and SUPPLIES

7.1 Assay Platform

Siemens Atellica CH Analyzer

7.2 Equipment

- Refrigerator capable of sustaining 2–8°C.
- Freezer capable of sustaining range not to exceed -20 to -70°C.
- Centrifuge

7.3 Supplies

- System Fluids
- Assorted calibrated pipettes (MLA or equivalent) and disposable tips

8. PROCEDURE

Atellica CH Alkaline Phosphatase, concentrated (ALP-2c) is required to perform this test.

Alkaline Phosphatase is performed on the Atellica CH Analyzer after the method is calibrated and Quality Controls are acceptable.

NOTE: For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

8.1	Instrument Set-up Protocol
1.	Perform any required instrument maintenance.
2.	Ensure that the instrument has sufficient primary and ancillary reagents.
3.	Check status of cuvettes and tips. Check waste levels. Fill or empty as appropriate.

8.1	Instrument Set-up Protocol
4.	Check calibration status and re-calibrate as needed.

8.2	Specimen Testing
1.	Centrifuge the specimens.
2.	Load the sample in the Atellica rack and place the rack into the Sample Handler to initiate testing. **NOTE: If not equipped with an in-line decapper unit, samples must be de-capped prior to loading on the Atellica system
3.	Refer to the general operating procedure for detailed steps.
4.	Follow protocol in section 10.6 “Repeat Criteria and Resulting” for samples with results above the analytical measurement range (AMR). Investigate any flagged results and repeat as necessary.
5.	Append the appropriate English text code qualifier messages to any samples requiring a comment regarding sample quality and/or any other pertinent factors.

NOTE: In the event that the test system becomes inoperable, notify supervision or designee for further direction. Patient specimens must be stored in a manner that maintains the integrity of the specimen.

9. CALCULATIONS

The instrument automatically calculates the concentration of Alkaline Phosphatase in U/L.

10. REPORTING RESULTS AND REPEAT CRITERIA

10.1 Interpretation of Data

None required

10.2 Rounding

No rounding is necessary. Instrument reports results as a whole number.

10.3 Units of Measure

U/L

10.4 Clinically Reportable Range (CRR)

10 – 10,000 U/L

10.5 Review Patient Data

Each result is reviewed for error messages. Resolve any problems noted before issuing patient reports.

10.6 Repeat Criteria and Resulting

All repeats must replicate the original result within the total allowable error (TEa) of the assay. Refer to TEa listing for specific information.

Values that fall below or within the AMR or CRR may be reported without repeat. Values that exceed the upper ranges must be repeated.

IF the result is ...	THEN...
< 10 U/L	Assure there is sufficient sample devoid of bubbles, cellular debris, and/or fibrin clots. Report as: < 10 U/L
≥ 1000 U/L	On Board Automated Dilution: Results ≥ 1000 U/L will automatically have repeat testing performed into the instrument using dilution factor of 10. No multiplication is necessary.
> 10,000 U/L	If the recommended dilution does not give results within the clinically reportable range, report as: "> 10,000 U/L -REP" Bring to the attention of Tech in Charge (TIC) or Group Lead to check for integrity issues prior to release of results.

Message	Code
Verified by repeat analysis	Append -REP to the result.

11. EXPECTED VALUES

11.1 Reference Ranges

Age	Female	Male
Adult (>18 years):	38 - 136 U/L	38 - 136 U/L
Pediatric:		
16 – 19 years	82 - 169	93 - 317
14 – 15 years	103 - 283	169 - 618
12 – 13 years	141 - 499	245 - 584
10 – 11 years	169 - 657	174 - 624
7 – 9 years	218 - 499	218 - 499
4 – 6 years	191 - 450	191 - 450
1 – 3 years	185 - 383	185 - 383
7 – 11 months	101 - 431	101 - 394
4 – 6 months	125 - 449	94 - 425
1 – 3 months	125 - 547	101 - 467
8 – 30 days	107 - 474	138 - 486
0–7 days	107 - 357	121 - 351

11.2 Critical Values

None established

11.3 Standard Required Messages

None established

12. CLINICAL SIGNIFICANCE

Serum alkaline phosphatase levels are of interest in the diagnosis of hepatobiliary disorders and bone disease associated with increased osteoblastic activity. Moderate elevations of alkaline phosphatase may be seen in several conditions that do not involve the liver or bone. Among these are Hodgkin's disease, congestive heart failure, ulcerative colitis, regional enteritis, and intra-abdominal bacterial infections. Elevations are also observed during the third trimester of pregnancy.

13. PROCEDURE NOTES

- **FDA Status:** FDA Approved/cleared
- **Validated Test Modifications:** None

The instrument reporting system contains error messages to warn the operator of specific malfunctions. Any report slip containing such error messages should be held for follow-up.

14. LIMITATIONS OF METHOD

14.1 Analytical Measurement Range (AMR)

10 – 1000 U/L

14.2 Precision

Material	Mean U/L	Standard Deviation (%CV)	
		Repeatability	Within-Lab
Serum Pool	87	0.37	1.3
Control 1	277	0.55	0.7
Plasma Pool	841	1.5	1.5

14.3 Interfering Substances

HIL Interference:

Interfering substances at the levels indicated in the table below were tested in accordance with CLSI Document EP07-A2.

Substance tested	Substance Concentration	U/L	Bias %
Hemoglobin	1000 mg/dL	264	-5
Bilirubin (unconjugated)	80 mg/dL	251	9
Bilirubin (conjugated)	80 mg/dL	265	6
Lipemia Intralipid®	600 mg/dL	250	1

14.4 Clinical Sensitivity/Specificity/Predictive Values

Detection Capability

The assay is designed to have a limit of blank (LoB) < 3 U/L, a limit of detection (LoD) \leq 8 U/L, and a limit of quantitation (LoQ) 10 U/L with \pm 40% total allowable error. The LoD corresponds to the lowest concentration of alkaline phosphatase that can be detected with a probability of 95%. The LoD for the Atellica CH ALP-2c assay is 0.4 U/L, and was determined using 120 determinations, with 60 blank and 60 low level replicates, and a LoB of 0 U/L. The LoQ corresponds to the lowest amount of analyte in a sample that can be accurately quantitated with a total allowable error \leq 40%. The LoQ of the Atellica CH ALP-2c assay is 6.2 U/L, based on 180 determinations, and was determined using multiple patient samples that were assayed using total analytical error definition of bias + 2SD.

15. SAFETY

Refer to your local and corporate safety manuals and Safety Data Sheet (SDS) for detailed information on safety practices and procedures and a complete description of hazards.

Atellica ALP-2c reagent causes serious eye irritation. Causes skin irritation. Harmful to aquatic life with long lasting effects. Wear protective gloves/protective clothing/eye protection/face protection. Wash hands thoroughly after handling. Avoid release to the environment. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention.

Contains: 2-amino-2-methylpropanol; sulfuric acid; zinc salt (1:1); heptahydrate (R1).

Also contains 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-2H-isothiazol-3-one (ProClin 300) which may produce an allergic reaction.

16. RELATED DOCUMENTS

1. Atellica Solution Operating, QC, Calibration and Maintenance procedure
2. Laboratory Quality Control Program
3. QC Schedule for Siemens Atellica Solution
4. Laboratory Safety Manual
5. Safety Data Sheets (SDS)
6. Atellica Solution Limits Chart
7. Quest Diagnostics Records Management Procedure
8. Atellica Solution System Error Messages Chart
9. Centrifuge Use, Maintenance and Function Checks (Lab policy)
10. Specimen Acceptability Requirements (Lab policy)
11. Repeat Testing Requirement (Lab policy)
12. Current Allowable Total Error Specifications at http://questnet1.qdx.com/Business_Groups/Medical/qc/docs/qc_bpt_tea.xls
13. Current package insert of Alkaline Phosphatase, Concentrated (ALP-2c) Reagent

17. REFERENCES

1. Ghoshal, Amit K. and Soldin, Steven J., Evaluation of the Dade Behring Dimension[®] RxL: Integrated chemistry system-pediatric reference ranges. Clinica Chimica Acta 2003; 331:144.
2. Package Insert, Alkaline Phosphatase, Concentrated Reagent, Siemens Healthcare Diagnostics Inc., 07/2019.
3. Package Insert, Alkaline Phosphatase-2 Calibrator (ALP-2 CAL), Siemens Healthcare Diagnostics Inc., 07/2019.
4. Package Insert, InteliQ Assayed Multiquel Controls, Bio-Rad Laboratories, 07/2020

18. REVISION HISTORY

Version	Date	Section	Reason	Reviser	Approval

19. ADDENDA

None

Technical SOP

Title	Lipase (Lip) by Atellica CH Analyzer	
Prepared by	Ashkan Chini	Date: 4/28/2021
Owner	Robert SanLuis	Date: 4/28/2021

Laboratory Approval	Local Effective Date:	
Print Name and Title	Signature	Date
<i>Refer to the electronic signature page for approval and approval dates.</i>		

TABLE OF CONTENTS

1.	Test Information.....	2
2.	Analytical Principle	2
3.	Specimen Requirements.....	2
4.	Reagents	3
5.	Calibrators/Standards	4
6.	Quality Control	5
7.	Equipment And Supplies	7
8.	Procedure	7
9.	Calculations.....	8
10.	Reporting Results And Repeat Criteria.....	8
11.	Expected Values.....	9
12.	Clinical Significance.....	9
13.	Procedure Notes	9
14.	Limitations Of Method	9
15.	Safety	10
16.	Related Documents	10
17.	References.....	10
18.	Revision History	11
19.	Addenda	11

1. TEST INFORMATION

Assay	Method/Instrument	Test Code
Lipase	Atellica CH Analyzer	LIPA

Synonyms/Abbreviations
LIP

Department
Chemistry

2. ANALYTICAL PRINCIPLE

The chromogenic lipase substrate, DGGMR, (1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6'-methylresorufin) ester) is cleaved by the catalytic action of lipase to form 1,2-o-dilauryl-racglycerol and an unstable intermediate, glutaric acid-(6'-methylresorufin) ester. This decomposes spontaneously in an alkaline solution to form glutaric acid and methylresorufin. The lipase activity in the specimen is proportional to the production of methylresorufin in the reaction and is determined spectrophotometrically. The Atellica CH Lip measurement wavelengths are 571/694 nm.

3. SPECIMEN REQUIREMENTS

3.1 Patient Preparation

Component	Special Notations
Fasting/Special Diets	N/A
Specimen Collection and/or Timing	Normal procedures for collecting and storing serum and plasma may be used for samples to be analyzed by this method.
Special Collection Procedures	N/A
Other	N/A

3.2 Specimen Type & Handling

Criteria	
Type -Preferred -Other Acceptable	Plasma (Lithium Heparin) Serum
Collection Container	Plasma: Mint green top tube (PST) Serum: Red top tube, Serum separator tube (SST)

Criteria	
Volume	- Optimum - Minimum
	1.0 mL 0.5 mL
Transport Container and Temperature	Collection container or Plastic vial at room temperature
Stability & Storage Requirements	Room Temperature: 24 hours Refrigerated: 7 days Frozen: 1 year
Timing Considerations	N/A
Unacceptable Specimens & Actions to Take	Specimens that are unlabeled, improperly labeled, or those that do not meet the stated criteria are unacceptable. Request a recollection and credit the test with the appropriate LIS English text code for “test not performed” message. Examples: Quantity not sufficient-QNS; Wrong collection-UNAC. Document the request for recollection in the LIS.
Compromising Physical Characteristics	Gross hemolysis. Reject sample and request a recollection. Credit the test with the appropriate LIS English text code explanation of HMT (Specimen markedly hemolyzed)
Other Considerations	Allow Red Top or SST to clot completely prior to centrifugation. Before placing on system, ensure samples are free of: <ul style="list-style-type: none"> • Bubbles or foam • Fibrin or other particulate matter

NOTE: Labeling requirements for all reagents, calibrators and controls include: (1) Open date, (2) Substance name, (3) Lot number, (4) Date of preparation, (5) Expiration date, (6) Initials of tech, and (7) Any special storage instructions. Check all for visible signs of degradation. When placed onboard the analyzer, the instrument captures the date / time loaded and calculates and tracks the opened expiration.

4. REAGENTS

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

4.1 Reagent Summary

Reagents	Supplier & Catalog Number
Lipase (Lip)	Siemens, Atellica CH, Cat. No. 11097606

4.2 Reagent Preparation and Storage

Reagent	Lipase (Lip)
Storage	<ul style="list-style-type: none"> • Store at 2-8°C • Protect from light sources

Stability	Onboard per well: 9 days
Preparation	Reagent is liquid and ready to use.

5. CALIBRATORS/STANDARDS

5.1 Calibrators/Standards Used

Calibrator	Supplier and Catalog Number
ENZ 1 Calibrator (ENZ 1 CAL)	Siemens Atellica CH, Cat. No. 11099317

5.2 Calibrator Preparation and Storage

Calibrator	ENZ 1 Calibrator (ENZ 1 CAL)
Preparation	Calibrators are liquid and ready to use.
Storage/Stability	<ul style="list-style-type: none"> • Store at 2-8°C • Protect from heat and light sources. • Unopened: stable until expiration date stamped on the box. • Opened: remains stable for 30 days when recapped immediately after use.

5.3 Calibration Parameter

Criteria	Special Notations
Reference Material	ENZ 1 Calibrator (ENZ 1 CAL)
Assay Range	See Package Insert for specific assay ranges.
Suggested Calibration Level	See Reagent Package Insert for lot specific assigned values in U/L
Frequency	<ul style="list-style-type: none"> • When changing lot numbers of primary reagent packs. • At the end of the lot calibration interval (61 days), for a specified lot of calibrated reagent on the system. • At the end of pack calibration interval (9 days), for calibrated reagent packs on the system. • When indicated by quality control results. • After major maintenance or service. <p>At the end of the onboard stability interval, replace the reagent pack on the system with a new reagent pack. Recalibration is not required, unless the lot calibration interval is exceeded.</p>
Calibration Scheme	See Package Insert for specific calibration scheme.
Procedure	Refer to the Atellica Solution Operating, QC, Calibration and Maintenance procedure for specific instructions.

5.4 Tolerance Limits

IF.....	THEN.....
If result fall within assay-specific specification, and QC values are within acceptable limits,	proceed with analysis
If result falls outside assay-specific specification, or QC values are out of Acceptable limits,	troubleshoot the assay and/or instrument and repeat calibration

6. QUALITY CONTROL

6.1 Controls Used

Controls	Supplier and Catalog Number
InteliQ Assayed Multiquel Control Levels 1 & 3	Bio-Rad Laboratories Cat. No. 12008256, 12008258

6.2 Control Preparation and Storage

Control	InteliQ Assayed Multiquel Control Levels 1 & 3
Preparation	Allow to stand at room temperature (18-25C) until completely thawed but not more than one (1) hour. Once thawed, gently invert several times to ensure homogeneity.
Storage/Stability	Frozen: until the expiration date if unopened at -20 to -70C Thawed and Unopened: 30 days at 2-8C for lipase Thawed and Opened: 14 days at 2-8C for lipase Note: stability varies by assay

6.3 Frequency

Analyze all levels of QC material after every calibration and each day of testing (notated on the QC frequency sheets posted on the instruments).

Refer to the Siemens Atellica QC Schedule and the Siemens Atellica Quick Reference Guide.

6.4 Tolerance Limits and Criteria for Acceptable QC

Step	Action
1	Acceptable ranges for QC are programmed into the instrument's Quality Control software system and Unity Real Time, and may be posted near the instrument for use during computer downtime.
2	Run Rejection Criteria <ul style="list-style-type: none"> Anytime the established parameters are exceeded (if one QC result exceeds 2 SD), the run is considered out of control (failed) and patient results must not be reported.

Step	Action
	<ul style="list-style-type: none"> The technologist must follow the procedure in the Laboratory QC Program to resolve the problem.
3	<p>Corrective Action:</p> <ul style="list-style-type: none"> All rejected runs must be effectively addressed through corrective action. Steps taken in response to QC failures must be documented. Patient samples in failed analytical runs must be <u>reanalyzed according to the Laboratory QC Program</u>. Supervisors may override rejection of partial or complete runs only with detailed documentation and criteria for overrides that are approved by the Medical Director. Consult corrective action guidelines in Laboratory QC Program. Follow corrective action guidelines in the Laboratory QC Program. Corrective action documentation must follow the Laboratory Quality Control Program.
4	<p>Review of QC</p> <ul style="list-style-type: none"> QC must be reviewed weekly by the Group Lead or designee and monthly by the Supervisor/Manager or designee. If the SD and/or CV are greater than established ranges, investigate the cause for the imprecision and document implementation of corrective actions.

6.5 Documentation

- QC tolerance limits are programmed into the instrument and Unity Real Time; it calculates cumulative mean, SD and CV and stores all information for easy retrieval.
- Quality control records are reviewed daily at the bench, weekly by the Group Lead or designee, and monthly by the Supervisor/Manager or designee.
- Refer to complete policies and procedures for QC documentation and for record retention requirements in the Laboratory QC Program.

6.6 Quality Assurance Program

- Each new lot number of reagent or new shipment of the same lot of reagent must be tested with external control materials and previously analyzed samples. Performance of the new lot must be equivalent to the previous lot; utilize published TEA for acceptability criteria.
- Training must be successfully completed and documented prior to performing this test. This procedure must be incorporated into the departmental competency assessment program.
- The laboratory participates in CAP proficiency testing. All proficiency testing materials must be treated in the same manner as patient samples.
- Monthly QC must be presented to the Medical Director or designee for review and signature.

- Monthly QC mean and SD are sent to Bio-Rad Laboratories for peer group comparison.
- Consult the Laboratory QC Program for complete details.

7. EQUIPMENT and SUPPLIES

7.1 Assay Platform

Siemens Atellica CH Analyzer

7.2 Equipment

- Refrigerator capable of sustaining 2–8°C.
- Freezer capable of sustaining range not to exceed -20 to -70°C.
- Centrifuge

7.3 Supplies

- System Fluids
- Assorted calibrated pipettes (MLA or equivalent) and disposable tips

8. PROCEDURE

Atellica CH Lipase (Lip) is required to perform this test.

Lipase is performed on the Atellica CH Analyzer after the method is calibrated and Quality Controls are acceptable.

NOTE: For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

8.1	Instrument Set-up Protocol
1.	Perform any required instrument maintenance.
2.	Ensure that the instrument has sufficient primary and ancillary reagents.
3.	Check status of cuvettes and tips. Check waste levels. Fill or empty as appropriate.
4.	Check calibration status and re-calibrate as needed.

8.2	Specimen Testing
1.	Centrifuge the specimens.
2.	Load the sample in the Atellica rack and place the rack into the Sample Handler to initiate testing. **NOTE: If not equipped with an in-line decapper unit, samples must be de-capped prior to loading on the Atellica system
3.	Refer to the general operating procedure for detailed steps.

8.2	Specimen Testing
4.	Follow protocol in section 10.6 “Repeat Criteria and Resulting” for samples with results above the analytical measurement range (AMR). Investigate any flagged results and repeat as necessary.
5.	Append the appropriate English text code qualifier messages to any samples requiring a comment regarding sample quality and/or any other pertinent factors.

NOTE: In the event that the test system becomes inoperable, notify supervision or designee for further direction. Patient specimens must be stored in a manner that maintains the integrity of the specimen.

9. CALCULATIONS

The instrument automatically calculates the concentration of Lipase in U/L.

10. REPORTING RESULTS AND REPEAT CRITERIA

10.1 Interpretation of Data

None required

10.2 Rounding

No rounding is necessary. Instrument reports results as a whole number.

10.3 Units of Measure

U/L

10.4 Clinically Reportable Range (CRR)

8 – 35,000 U/L

10.5 Review Patient Data

Each result is reviewed for error messages. Resolve any problems noted before issuing patient reports.

10.6 Repeat Criteria and Resulting

All repeats must replicate the original result within the total allowable error (TEa) of the assay. Refer to TEa listing for specific information.

Values that fall below or within the AMR or CRR may be reported without repeat. Values that exceed the upper ranges must be repeated.

IF the result is ...	THEN...
< 8 U/L	Assure there is sufficient sample devoid of bubbles, cellular debris, and/or fibrin clots. Report as: < 8 U/L

IF the result is ...	THEN...
≥ 700 U/L	On Board Automated Dilution: Results ≥ 700 U/L will automatically have repeat testing performed into the instrument using dilution factor of 50. No multiplication is necessary.
> 35,000 U/L	If the recommended dilution does not give results within the clinically reportable range, report as: “> 35,000 U/L -REP” Bring to the attention of Tech in Charge (TIC) or Group Lead to check for integrity issues prior to release of results.

Message	Code
Verified by repeat analysis	Append -REP to the result.

11. EXPECTED VALUES

11.1 Reference Ranges

11 – 75 U/L

11.2 Critical Values

None established

11.3 Standard Required Messages

None established

12. CLINICAL SIGNIFICANCE

Pancreatic lipase degrades dietary triglycerides to glycerol and free fatty acids in the duodenum in the presence of the bile salts.

Lipase measurements are used to diagnose and monitor treatment of diseases of the pancreas, such as acute and chronic pancreatitis and obstruction of the pancreatic duct.

13. PROCEDURE NOTES

- **FDA Status:** FDA Approved/cleared
- **Validated Test Modifications:** None

The instrument reporting system contains error messages to warn the operator of specific malfunctions. Any report slip containing such error messages should be held for follow-up.

14. LIMITATIONS OF METHOD

14.1 Analytical Measurement Range (AMR)

8 – 700 U/L

14.2 Precision

Material	Mean U/L	Standard Deviation (%CV)	
		Repeatability	Within-Lab
Control 1	36	1.12	3.1
Plasma Pool	204	1.86	0.9
Serum Pool	655	3.90	0.6

14.3 Interfering Substances

HIL Interference:

Interfering substances at the levels indicated in the table below were tested in accordance with CLSI Document EP07-A2.

Substance tested	Substance Concentration	U/L	Bias %
Hemoglobin	200 mg/dL	50	7
Bilirubin (conjugated)	25 mg/dL	54	3
Bilirubin (unconjugated)	25 mg/dL	51	-1
Lipemia Intralipid®	1000 mg/dL	52	10

14.4 Clinical Sensitivity/Specificity/Predictive Values

Detection Capability

The assay is designed to have a limit of blank (LoB) < limit of detection (LoD) and $LoD \leq 8$ U/L. The LoD corresponds to the lowest concentration of lipase that can be detected with a probability of 95%. The LoD for the Atellica CH Lip assay is 6 U/L, and was determined using 120 determinations, with 60 blank and 60 low level replicates, and a LoB of 3 U/L.

15. SAFETY

Refer to your local and corporate safety manuals and Safety Data Sheet (SDS) for detailed information on safety practices and procedures and a complete description of hazards.

16. RELATED DOCUMENTS

1. Atellica Solution Operating, QC, Calibration and Maintenance procedure
2. Laboratory Quality Control Program
3. QC Schedule for Siemens Atellica Solution
4. Laboratory Safety Manual
5. Safety Data Sheets (SDS)
6. Atellica Solution Limits Chart
7. Quest Diagnostics Records Management Procedure
8. Atellica Solution System Error Messages Chart
9. Centrifuge Use, Maintenance and Function Checks (Lab policy)

- 10. Specimen Acceptability Requirements (Lab policy)
- 11. Repeat Testing Requirement (Lab policy)
- 12. Current Allowable Total Error Specifications at http://questnet1.qdx.com/Business_Groups/Medical/qc/docs/qc_bpt_tea.xls
- 13. Current package insert of Lipase Reagent

17. REFERENCES

- 1. Package Insert, Lipase Reagent, Siemens Healthcare Diagnostics Inc., 06/2019.
- 2. Package Insert, ENZ 1 Calibrator (ENZ 1 CAL), Siemens Healthcare Diagnostics Inc., 07/2019.
- 3. Package Insert, InteliQ Assayed Multiquel Controls, Bio-Rad Laboratories, 07/2020

18. REVISION HISTORY

Version	Date	Section	Reason	Reviser	Approval
1	5/16/21	11.1	Changed range to match validation data	L Barrett	R SanLuis

19. ADDENDA

None

Technical SOP

Title	Gamma-Glutamyl Transferase (GGT) by Atellica CH Analyzer	
Prepared by	Ashkan Chini	Date: 4/27/2021
Owner	Robert SanLuis	Date: 4/27/2021

Laboratory Approval	Local Effective Date:	
Print Name and Title	Signature	Date
<i>Refer to the electronic signature page for approval and approval dates.</i>		

TABLE OF CONTENTS

1.	Test Information.....	2
2.	Analytical Principle	2
3.	Specimen Requirements.....	2
4.	Reagents	3
5.	Calibrators/Standards	4
6.	Quality Control	5
7.	Equipment And Supplies	7
8.	Procedure	7
9.	Calculations.....	8
10.	Reporting Results And Repeat Criteria.....	8
11.	Expected Values.....	9
12.	Clinical Significance.....	10
13.	Procedure Notes	10
14.	Limitations Of Method	10
15.	Safety	11
16.	Related Documents	11
17.	References.....	11
18.	Revision History	12
19.	Addenda	12

1. TEST INFORMATION

Assay	Method/Instrument	Test Code
Gamma-Glutamyl Transferase	Atellica CH Analyzer	GGT

Synonyms/Abbreviations
GGT

Department
Chemistry

2. ANALYTICAL PRINCIPLE

In the reaction with synthetic substrate (L- γ -glutamyl-3-carboxy-4-nitroanilide), glycylglycine acts as an acceptor for the γ -glutamyl residue and 5-Amino-2-Nitrobenzoate (ANB) is liberated. The liberated product has an absorption maximum near 400 nm. The rate of formation is measured photometrically at 410/478 nm as a zero-order kinetic assay.

3. SPECIMEN REQUIREMENTS

3.1 Patient Preparation

Component	Special Notations
Fasting/Special Diets	N/A
Specimen Collection and/or Timing	Normal procedures for collecting and storing serum and plasma may be used for samples to be analyzed by this method.
Special Collection Procedures	N/A
Other	N/A

3.2 Specimen Type & Handling

Criteria	
Type -Preferred -Other Acceptable	Plasma (Lithium Heparin) Serum
Collection Container	Plasma: Mint green top tube (PST) Serum: Red top tube, Serum separator tube (SST)
Volume - Optimum - Minimum	1.0 mL 0.5 mL

Criteria	
Transport Container and Temperature	Collection container or Plastic vial at room temperature
Stability & Storage Requirements	Room Temperature: 7 days
	Refrigerated: 7 days
	Frozen: 6 months
Timing Considerations	N/A
Unacceptable Specimens & Actions to Take	Specimens that are unlabeled, improperly labeled, or those that do not meet the stated criteria are unacceptable. Request a recollection and credit the test with the appropriate LIS English text code for “test not performed” message. Examples: Quantity not sufficient-QNS; Wrong collection-UNAC. Document the request for recollection in the LIS.
Compromising Physical Characteristics	Gross hemolysis. Reject sample and request a recollection. Credit the test with the appropriate LIS English text code explanation of HMT (Specimen markedly hemolyzed)
Other Considerations	Allow Red Top or SST to clot completely prior to centrifugation. Before placing on system, ensure samples are free of: <ul style="list-style-type: none"> • Bubbles or foam • Fibrin or other particulate matter

NOTE: Labeling requirements for all reagents, calibrators and controls include: (1) Open date, (2) Substance name, (3) Lot number, (4) Date of preparation, (5) Expiration date, (6) Initials of tech, and (7) Any special storage instructions. Check all for visible signs of degradation. When placed onboard the analyzer, the instrument captures the date / time loaded and calculates and tracks the opened expiration.

4. REAGENTS

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

4.1 Reagent Summary

Reagents	Supplier & Catalog Number
Gamma-Glutamyl Transferase (GGT)	Siemens, Atellica CH, Cat. No. 11097597

4.2 Reagent Preparation and Storage

Reagent	Gamma-Glutamyl Transferase (GGT)
Storage	Store at 2-8°C
Stability	Onboard per well: 22 days
Preparation	Reagent is liquid and ready to use.

5. CALIBRATORS/STANDARDS

5.1 Calibrators/Standards Used

Calibrator	Supplier and Catalog Number
ENZ 1 Calibrator (ENZ 1 CAL)	Siemens Atellica CH, Cat. No. 11099317

5.2 Calibrator Preparation and Storage

Calibrator	ENZ 1 Calibrator (ENZ 1 CAL)
Preparation	Calibrators are liquid and ready to use.
Storage/Stability	<ul style="list-style-type: none"> • Store at 2-8°C • Protect from heat and light sources. • Unopened: stable until expiration date stamped on the box. • Opened: remains stable for 30 days when recapped immediately after use.

5.3 Calibration Parameter

Criteria	Special Notations
Reference Material	ENZ 1 Calibrator (ENZ 1 CAL)
Assay Range	See Package Insert for specific assay ranges.
Suggested Calibration Level	See Reagent Package Insert for lot specific assigned values in U/L
Frequency	<ul style="list-style-type: none"> • When changing lot numbers of primary reagent packs. • At the end of the lot calibration interval (60 days), for a specified lot of calibrated reagent on the system. • At the end of pack calibration interval (22 days), for calibrated reagent packs on the system. • When indicated by quality control results. • After major maintenance or service. <p>At the end of the onboard stability interval, replace the reagent pack on the system with a new reagent pack. Recalibration is not required, unless the lot calibration interval is exceeded.</p>
Calibration Scheme	See Package Insert for specific calibration scheme.
Procedure	Refer to the Atellica Solution Operating, QC, Calibration and Maintenance procedure for specific instructions.

5.4 Tolerance Limits

IF.....	THEN.....
If result fall within assay-specific specification, and QC values are within acceptable limits,	proceed with analysis

IF.....	THEN.....
If result falls outside assay-specific specification, or QC values are out of Acceptable limits,	troubleshoot the assay and/or instrument and repeat calibration

6. QUALITY CONTROL

6.1 Controls Used

Controls	Supplier and Catalog Number
InteliQ Assayed Multiquel Control Levels 1 & 3	Bio-Rad Laboratories Cat. No. 12008256, 12008258

6.2 Control Preparation and Storage

Control	InteliQ Assayed Multiquel Control Levels 1 & 3
Preparation	Allow to stand at room temperature (18-25C) until completely thawed but not more than one (1) hour. Once thawed, gently invert several times to ensure homogeneity.
Storage/Stability	Frozen: until the expiration date if unopened at -20 to -70C Thawed and Unopened: 30 days at 2-8C for GGT Thawed and Opened: 14 days at 2-8C for GGT Note: stability varies by assay

6.3 Frequency

Analyze all levels of QC material after every calibration and each day of testing (notated on the QC frequency sheets posted on the instruments).

Refer to the Siemens Atellica QC Schedule and the Siemens Atellica Quick Reference Guide.

6.4 Tolerance Limits and Criteria for Acceptable QC

Step	Action
1	Acceptable ranges for QC are programmed into the instrument's Quality Control software system and Unity Real Time, and may be posted near the instrument for use during computer downtime.
2	Run Rejection Criteria <ul style="list-style-type: none"> Anytime the established parameters are exceeded (if one QC result exceeds 2 SD), the run is considered out of control (failed) and patient results must not be reported. The technologist must follow the procedure in the Laboratory QC Program to resolve the problem.

Step	Action
3	<p>Corrective Action:</p> <ul style="list-style-type: none"> • All rejected runs must be effectively addressed through corrective action. Steps taken in response to QC failures must be documented. Patient samples in failed analytical runs must be <u>reanalyzed according to the Laboratory QC Program</u>. Supervisors may override rejection of partial or complete runs only with detailed documentation and criteria for overrides that are approved by the Medical Director. Consult corrective action guidelines in Laboratory QC Program. Follow corrective action guidelines in the Laboratory QC Program. • Corrective action documentation must follow the Laboratory Quality Control Program.
4	<p>Review of QC</p> <ul style="list-style-type: none"> • QC must be reviewed weekly by the Group Lead or designee and monthly by the Supervisor/Manager or designee. • If the SD and/or CV are greater than established ranges, investigate the cause for the imprecision and document implementation of corrective actions.

6.5 Documentation

- QC tolerance limits are programmed into the instrument and Unity Real Time; it calculates cumulative mean, SD and CV and stores all information for easy retrieval.
- Quality control records are reviewed daily at the bench, weekly by the Group Lead or designee, and monthly by the Supervisor/Manager or designee.
- Refer to complete policies and procedures for QC documentation and for record retention requirements in the Laboratory QC Program.

6.6 Quality Assurance Program

- Each new lot number of reagent or new shipment of the same lot of reagent must be tested with external control materials and previously analyzed samples. Performance of the new lot must be equivalent to the previous lot; utilize published TEA for acceptability criteria.
- Training must be successfully completed and documented prior to performing this test. This procedure must be incorporated into the departmental competency assessment program.
- The laboratory participates in CAP proficiency testing. All proficiency testing materials must be treated in the same manner as patient samples.
- Monthly QC must be presented to the Medical Director or designee for review and signature.
- Monthly QC mean and SD are sent to Bio-Rad Laboratories for peer group comparison.

- Consult the Laboratory QC Program for complete details.

7. EQUIPMENT and SUPPLIES

7.1 Assay Platform

Siemens Atellica CH Analyzer

7.2 Equipment

- Refrigerator capable of sustaining 2–8°C.
- Freezer capable of sustaining range not to exceed -20 to -70°C.
- Centrifuge

7.3 Supplies

- System Fluids
- Assorted calibrated pipettes (MLA or equivalent) and disposable tips

8. PROCEDURE

Atellica CH Gamma-Glutamyl Transferase (GGT) is required to perform this test.

GGT is performed on the Atellica CH Analyzer after the method is calibrated and Quality Controls are acceptable.

NOTE: For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

8.1	Instrument Set-up Protocol
1.	Perform any required instrument maintenance.
2.	Ensure that the instrument has sufficient primary and ancillary reagents.
3.	Check status of cuvettes and tips. Check waste levels. Fill or empty as appropriate.
4.	Check calibration status and re-calibrate as needed.

8.2	Specimen Testing
1.	Centrifuge the specimens.
2.	Load the sample in the Atellica rack and place the rack into the Sample Handler to initiate testing. **NOTE: If not equipped with an in-line decapper unit, samples must be de-capped prior to loading on the Atellica system
3.	Refer to the general operating procedure for detailed steps.

8.2	Specimen Testing
4.	Follow protocol in section 10.6 “Repeat Criteria and Resulting” for samples with results above the analytical measurement range (AMR). Investigate any flagged results and repeat as necessary.
5.	Append the appropriate English text code qualifier messages to any samples requiring a comment regarding sample quality and/or any other pertinent factors.

NOTE: In the event that the test system becomes inoperable, notify supervision or designee for further direction. Patient specimens must be stored in a manner that maintains the integrity of the specimen.

9. CALCULATIONS

The instrument automatically calculates the concentration of Gamma-Glutamyl Transferase in U/L.

10. REPORTING RESULTS AND REPEAT CRITERIA

10.1 Interpretation of Data

None required

10.2 Rounding

No rounding is necessary. Instrument reports results as a whole number.

10.3 Units of Measure

U/L

10.4 Clinically Reportable Range (CRR)

7 – 3600 U/L

10.5 Review Patient Data

Each result is reviewed for error messages. Resolve any problems noted before issuing patient reports.

10.6 Repeat Criteria and Resulting

All repeats must replicate the original result within the total allowable error (TEa) of the assay. Refer to TEa listing for specific information.

Values that fall below or within the AMR or CRR may be reported without repeat.
Values that exceed the upper ranges must be repeated.

IF the result is ...	THEN...
< 7 U/L	Assure there is sufficient sample devoid of bubbles, cellular debris, and/or fibrin clots. Report as: < 7 U/L
≥ 1200 U/L	On Board Automated Dilution: Results ≥ 1200 U/L will automatically have repeat testing performed into the instrument using dilution factor of 3. No multiplication is necessary.
> 3600 U/L	If the recommended dilution does not give results within the clinically reportable range, report as: "> 3600 U/L -REP" Bring to the attention of Tech in Charge (TIC) or Group Lead to check for integrity issues prior to release of results.

Message	Code
Verified by repeat analysis	Append -REP to the result.

11. EXPECTED VALUES

11.1 Reference Ranges

Age	Female	Male
Adult (>19 years):	5 - 55 U/L	5 - 85 U/L
Pediatric:		
16 – 19 years	6 - 23	6 - 30
14 – 15 years	10 - 22	8 - 29
12 – 13 years	10 - 20	12 - 39
10 – 11 years	12 - 23	12 - 25
7 – 9 years	9 - 20	9 - 20
4 – 6 years	5 - 17	5 - 17
1 – 3 years	2 - 15	2 - 15
7 – 11 months	8 - 59	8 - 38
4 – 6 months	13 - 123	5 - 93
1 – 3 months	16 - 140	16 - 147
8 days – 30 days	16 - 140	23 - 174
0 – 7 days	18 - 148	25 - 168

11.2 Critical Values

None established

11.3 Standard Required Messages

None established

12. CLINICAL SIGNIFICANCE

Gamma-glutamyl transferase (GGT) is markedly increased in lesions that cause intrahepatic or extrahepatic obstruction of bile ducts, including parenchymatous liver diseases with a major cholestatic component (e.g. cholestatic hepatitis). Lesser elevations of GGT are seen in other liver diseases, and in infectious mononucleosis, hyperthyroidism, myotonic dystrophy, and after renal allograft. Drugs causing hepatocellular damage and cholestasis may also cause GGT elevation. GGT is a very sensitive test for liver damage, and unexpected, unexplained mild elevations are common. Alcohol consumption is a common culprit. Decreased GGT is not clinically significant.

13. PROCEDURE NOTES

- **FDA Status:** FDA Approved/cleared
- **Validated Test Modifications:** None

The instrument reporting system contains error messages to warn the operator of specific malfunctions. Any report slip containing such error messages should be held for follow-up.

14. LIMITATIONS OF METHOD

14.1 Analytical Measurement Range (AMR)

7 – 1200 U/L

14.2 Precision

Material	Mean U/L	Standard Deviation (%CV)	
		Repeatability	Within-Lab
Plasma	42	0.8	1.9
QC	81	0.8	1.0
Serum	1044	1.8	0.2

14.3 Interfering Substances

HIL Interference:

Interfering substances at the levels indicated in the table below were tested in accordance with CLSI Document EP07-A2.

Substance tested	Substance Concentration	U/L	Bias %
Hemoglobin	750 mg/dL	53	9
Bilirubin (conjugated)	10 mg/dL	56	4
Bilirubin (unconjugated)	10 mg/dL	58	-2
Lipemia Intralipid®	500 mg/dL	57	2

14.4 Clinical Sensitivity/Specificity/Predictive Values

Detection Capability

The assay is designed to have a limit of blank (LoB) < limit of detection (LoD) and $LoD \leq 7$ U/L. The LoD corresponds to the lowest concentration of gamma-glutamyl transferase that can be detected with a probability of 95%. The LoD for the Atellica CH GGT assay is 2 U/L.

15. SAFETY

Refer to your local and corporate safety manuals and Safety Data Sheet (SDS) for detailed information on safety practices and procedures and a complete description of hazards.

Atellica GGT reagent may cause an allergic skin reaction. Wear protective gloves/protective clothing/eye protection/face protection. Contaminated work clothing should not be allowed out of the workplace. IF ON SKIN: Wash with plenty of soap and water. If skin irritation or rash occurs: Get medical advice/attention. Wash contaminated clothing before reuse.

Contains: reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-2H-isothiazol-3-one (3:1) (R1 and R2)

16. RELATED DOCUMENTS

1. Atellica Solution Operating, QC, Calibration and Maintenance procedure
2. Laboratory Quality Control Program
3. QC Schedule for Siemens Atellica Solution
4. Laboratory Safety Manual
5. Safety Data Sheets (SDS)
6. Atellica Solution Limits Chart
7. Quest Diagnostics Records Management Procedure
8. Atellica Solution System Error Messages Chart
9. Centrifuge Use, Maintenance and Function Checks (Lab policy)
10. Specimen Acceptability Requirements (Lab policy)
11. Repeat Testing Requirement (Lab policy)
12. Current Allowable Total Error Specifications at http://questnet1.qdx.com/Business_Groups/Medical/qc/docs/qc_bpt_tea.xls
13. Current package insert of Gamma-Glutamyl Transferase Reagent

17. REFERENCES

1. Ghoshal, Amit K. and Soldin, Steven J., Evaluation of the Dade Behring Dimension[®] RxL: Integrated chemistry system-pediatric reference ranges. Clinica Chimica Acta 2003; 331:144.
2. Package Insert, Gamma-Glutamyl Transferase Reagent, Siemens Healthcare Diagnostics Inc., 07/2019.
3. Package Insert, ENZ 1 Calibrator (ENZ 1 CAL), Siemens Healthcare Diagnostics Inc., 07/2019.
4. Package Insert, IntelliQ Assayed Multiqual Controls, Bio-Rad Laboratories, 07/2020

18. REVISION HISTORY

Version	Date	Section	Reason	Reviser	Approval

19. ADDENDA

None